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ABSTRACT 
MIMICKING THE ARTERIAL MICROENVIRONMENT WITH PEG-PC TO 
INVESTIGATE THE ROLES OF PHYSICOCHEMICAL STIMULI IN SMC 
PHENOTYPE AND BEHAVIOR 
MAY 2015 
WILLIAM GERARD HERRICK, B.S., THE JOHNS HOPKINS UNIVERSITY 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Assistant Professor Shelly R. Peyton 
 
 The goal of this dissertation was to parse the roles of physical, mechanical and 
chemical cues in the phenotype plasticity of smooth muscle cells (SMCs) in 
atherosclerosis. We first developed and characterized a novel synthetic hydrogel with 
desirable traits for studying mechanotransduction in vitro. This hydrogel, PEG-PC, is a co-
polymer of poly(ethylene glycol) and phosphorylcholine with an incredible range of 
Young’s moduli (~1 kPa - 9 MPa) that enables reproduction of nearly any tissue stiffness, 
exceptional optical and anti-fouling properties, and support for covalent attachment of 
extracellular matrix (ECM) proteins. To our knowledge, this combination of mechanical 
range, low price, and ease-of-use is unmatched by any other hydrogel. We further used 
PEG-PC to evaluate the impact of substrate stiffness on the proliferation and adhesion 
properties of three cancer cell lines in 2D, from which we conclude that 
mechanotransduction is cell type-dependent and differences in focal adhesion-mediated 
signaling affect proliferation outcomes. 
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With PEG-PC as a substrate, we then designed a complex in vitro model to 
recapitulate characteristic changes in the surrounding microenvironment that SMCs 
experience during the progression of atherosclerosis. These changes include the 
composition of the ECM, the availability of soluble factors, and the surrounding 
mechanical environment. Our findings point to ECM composition as the primary regulator 
of SMC behaviors and characteristics, in part by modulating the effects of soluble factors. 
Unexpectedly, changes in substrate stiffness had a relatively modest effect. In spite of large 
ECM-directed differences in proliferation and motility, we did not find that these behaviors 
are inversely related to SMC marker expression, nor was marker expression substantially 
dependent on ECM composition despite being regulated by focal adhesion kinase 
signaling. Finally, our findings suggest that the transition from a migratory to a 
proliferative phenotype in atherosclerosis is mediated by the changing ECM composition, 
and we propose hypothetical, integrin-driven models to explain this switch. From these 
conclusions, we emphasize the importance of increasing the complexity of in vitro models 
to carefully match critical features of the in vivo microenvironments. We expect this 
approach to produce physiologically relevant behaviors, and in doing so we may identify 
novel, context-dependent therapeutic targets. 
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CHAPTER 1 
INTRODUCTION 
1.1 The devastating impact of atherosclerosis on human health 
Since at least 1900, the leading cause of non-infectious death nearly every year in 
the Western world has been heart disease or atherosclerosis-related [1]. In 2010 alone there 
were 596,577 deaths attributed to heart disease, of which 62.9% are attributed to ischemic 
heart disease and 5.6% are attributed to hypertensive disease, both most commonly caused 
by atherosclerosis. Examined further, 21% of these heart disease-related deaths were due 
to myocardial infarction, 42% due to ‘other forms of chronic ischemic heart disease,’ and 
30.3% due to ‘other heart diseases’ such as acute endocarditis, heart failure and ‘all other 
types of heart disease’ [2]. Furthermore, the picture worsens if we consider cerebrovascular 
diseases (128,932 deaths in 2009) and aortic aneurysm (10,073 deaths), other common 
results of atherosclerotic plaque disruption. Altogether this represents 738,852 deaths or 
29.2% of all deaths in the United States in 2011, a figure which matches the World Health 
Organization’s figures for atherosclerosis-related deaths worldwide in 2008 [3]. In 
contrast, all forms of malignant neoplasms (cancer) combined accounted for 576,691 
deaths or 22.3% in the United States in 2011.  
Heart disease and cancer are major public health problems that need considerable 
research and work to address. The scope of the problem is even greater when we consider 
that the rates of obesity [4] and type II diabetes [5] in the United States have risen steadily 
since 1990 – current estimates are that 20% of children [6] and 36% of adults [4] are obese. 
Both conditions are believed to be interrelated and are significant risk factors for heart 
disease and cancer. This is not especially surprising given the large number of similarities 
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between atherosclerosis and many types of cancer, including hyperproliferative cells and 
fibrotic tissues.  
 
1.2 What is atherosclerosis? 
1.2.1 The pathogenesis of atherosclerosis 
Atherosclerosis, literally “hardening of the arteries,” is characterized by the 
development of atherosclerotic plaques, also known as an atheroma. The disease earns its 
name from the progressive stiffening or hardening of the arteries affected by plaque 
formation, in particular when the plaques become fibrotic and calcified. Plaques begin as 
small, fatty lumps or streaks on the arterial wall, but under the wrong conditions these fatty 
streaks coalesce into larger fatty deposits and develop into plaques which protrude into the 
bloodstream and occlude blood flow (Fig. 1.1) [7]. Occlusion of blood flow from plaque 
protrusion can lead to hypertension and eventually ischemia, which has potentially life-
threatening consequences. Plaques can form anywhere in the large arteries, but are most 
problematic when they grow uncontrollably in the cerebral arteries (increasing risk for 
stroke) and coronary arteries (increasing risk for myocardial infarction) [7]. They can also 
develop in the aorta, increasing risk for type III aortic dissection [8], and abdominal aortic 
aneurysms [9]. Atherosclerosis is also a major cause of peripheral arterial disease [10], a 
leading cause of lower limb amputation in diabetic patients [11].  
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Figure 1.1: Illustration of a normal and blocked artery 
"Blausen 0052 Artery NormalvPartially-BlockedVessel" by BruceBlaus - Own work. 
Licensed under Creative Commons Attribution 3.0 via Wikimedia Commons - 
http://commons.wikimedia.org/wiki/File:Blausen_0052_Artery_NormalvPartially-
BlockedVessel.png#mediaviewer/File:Blausen_0052_Artery_NormalvPartially-
BlockedVessel.png 
 
1.2.2 The healthy vasculature 
The medium- and large-sized elastic arteries affected by atherosclerosis are 
comprised of 3 distinct tissue layers (Fig. 1.2). The outermost layer, the adventitia, is 
largely acellular and composed primarily of connective tissues, especially collagen. Its 
function is to anchor arteries to the bones and organs of the body and keep them in place. 
The innermost layer, the intima, is in contact with flowing blood and is composed of a 
single layer of endothelial cells attached to a thin basement membrane of connective 
tissues. The middle layer, the media, is responsible for imparting the elastic stretch-recoil 
properties that allow the vascular wall to  retain mechanical integrity under pulsatile 
blood flow. These properties are imparted by smooth muscle cells (SMCs) arranged in 
concentric layers sandwiched between connective tissues and thick sheets of elastin [7,12]. 
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These SMCs are in a ‘contractile’ phenotype, so-called because of their robust actomyosin 
contractile apparatus that imparts resilience to mechanical stretch and strain. 
The extracellular matrix proteins comprising the connective tissues are crucial to 
the unique mechanical properties of large arteries, but they also affect cell phenotype and 
behavior through integrin signaling and sequestration of growth factors. In an undamaged 
media, SMCs are in immediate contact with a thin layer of basement membrane (or 
reticular lamina; the correct nomenclature is unclear) comprised largely of laminin and the 
non-fibrillar type IV collagen. Both proteins are major components of Matrigel™, a protein 
mixture purified from Engelbreth-Holm-Swarm mouse sarcoma, which is commonly used 
for cell culture and known to promote differentiated phenotypes in vitro [13,14]. Indeed, 
the combination of laminin and collagen IV has been shown to promote expression of 
contractile markers in SMCs [15,16], but evidence points to laminins having the greatest 
impact [16–18], especially when the cells are exposed to cyclic stretch [19]. Their effects 
are most likely mediated by integrin signaling, but there may be other mechanisms at work. 
Collagen IV has also been implicated in phenotype maintenance of smooth muscle cells, 
but this finding has not been confirmed in other studies [18]. Regardless, collagen IV does 
make up about 50% of the basement membrane and forms suprastructures with laminins 
[20]. It may have anti-proliferative effects, in part, by binding and sequestering growth 
factors including PDGF and FGF [21]. 
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Figure 1.2: Illustration of the arrangement of SMCs and ECM proteins in the media 
A detailed depiction of the healthy arterial media. E = elastin fibers, F = collagen I fibers, 
M = basement membrane and collagen III mesh, Ce = SMC, C = circumferential cut, L = 
longitudinal cut. Figure adapted with permission from [12], Copyright © 1985 Wolters 
Kluwer Health. 
 
Immediately adjacent to the thin basement membrane layer resides a mesh-like 
network of collagen III fibrils (Fig. 1.2) [12], which is surrounded by thick sheets of elastic 
laminae composed of crosslinked elastin protein. Finally, thick bundles of collagen I are 
interspersed between the elastic laminae. These bundles of SMCs and connective tissues, 
collectively termed “lamellar units,” are primarily responsible for the elasticity and 
mechanical integrity of large arteries [22]. It is unclear if SMCs in the media are directly 
adhered to the collagen networks, but fibrillar forms of both types of collagen and elastin 
fibers have been demonstrated to promote the contractile phenotype in SMCs in vitro [18].  
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1.2.3 Physicochemical factors in atherosclerosis 
While it is not known with certainty how atherosclerosis starts, it is widely believed 
that vascular inflammation is the most likely initiator of plaque formation. The 
inflammatory response leading to atherosclerosis is initiated, in part, by low density 
lipoproteins (LDLs) and very low density lipoproteins (VLDLs) embedding in the vascular 
subendothelial space [7]. Atherosclerosis results when vascular inflammation is chronic, 
and the persistent inflammation seems likely to be the result of a combination of factors. 
Implicated pro-inflammatory factors include those mentioned above, plus oxidized low 
density lipoproteins (oxLDLs), advanced glycation end-products (AGEs) [23], and 
inflammatory factors such as interleukins and interferons [24].  
Regardless of the initial cause, fatty streaks form from the embedding of LDL and 
VLDL particles and their uptake by invading monocytes [7]. In the subendothelial space, 
monocytes differentiate into macrophages and impact plaque progression in multiple ways: 
they secrete growth factors and cytokines that ‘activate’ endothelial cells, which, in turn, 
also produce growth factors and cytokines; they express scavenger receptor A to increase 
the uptake of LDL particles [25]; they express matrix metalloproteinases (MMPs) and 
migrate towards the intima, digesting the connective tissues in their path; they increase 
uptake of LDL particles and can eventually turn into fat-laden ‘foam cells’ which apoptose 
at a higher rate and fill the subendothelial space with extracellular fat deposits [7]; and they 
may also secrete disordered fragments of elastin and collagen [26,27]. 
All of these factors serve to irreversibly damage the arterial wall and contribute to 
phenotype switching of SMCs in the media. SMCs respond to the soluble growth factors 
and cytokines – which have either diffused there or are secreted by invading macrophages 
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– by expressing MMPs [28], digesting their surrounding matrix and migrating towards the 
developing plaque [7]. These atherosclerosis-associated SMCs have dedifferentiated into 
the so-called ‘synthetic’ phenotype, which is similar to that of myofibroblasts. In some 
plaques, SMCs proliferate rapidly and secrete excess collagen, fibronectin, and elastin 
fragments that contribute to plaque size and form a fibrotic cap, which is the type plaque 
from which atherosclerosis derives its name [7]. However, they may also apoptose and/or 
take up LDL particles and become foam cells, much like macrophages, which may 
contribute to a softer plaque that is believed to be more prone to rupture [29]. Of course, 
the degradation of the medial connective tissues during their migration to the plaque results 
in the loss of mechanical integrity, which along with occlusion of blood flow will 
contribute to hypertension [30].  
The atherosclerotic plaque is a heterogeneous environment with dozens of soluble 
factors identified in vitro as having potential roles in disease progression. These soluble 
chemicals are believed to, on the whole, increase the rates proliferation of resident cells, as 
well as their uptake of LDL particles and synthesis of extracellular matrix proteins and 
lipids [31,32]. The majority of these soluble factors are classified as cytokines with roles 
in modulating the immune response at sites of vascular inflammation. Interleukins, secreted 
peptide cytokines, are one such class of immunomodulators produced by macrophages and 
endothelial cells. Interleukin-1s (IL-1), actually a family of 4 proteins, are believed to 
prolong the inflammatory response by inducing resident endothelial cells to produce more 
cytokines (IL-6, IL-8, monocyte chemoattractant protein, tumor necrosis factor), by 
upregulating MMP expression, and by promoting transendothelial migration of leukocytes 
and monocytes by upregulating ICAM-1 and VCAM-1 [33]. Interleukin-8 has similar 
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positive feedback effects on inflammation and can simultaneously activate several 
signaling pathways associated with cytoskeleton dynamics, protein synthesis and 
enhancement of growth factor signaling [34]. Interleukin-6 also has pro-inflammatory 
effects and is produced by immune cells and SMCs in plaques [35]. Tumor necrosis factor 
alpha (TNFα) is another cytokine produced by macrophages and endothelial cells 
implicated in proliferation, cell survival and production of pro-inflammatory eicosanoids 
and interleukins [36]. 
Growth factors are another major promoter of atherosclerotic lesion formation 
through their effects on cell proliferation, survival and migration. The most potent growth 
factor to SMCs in vitro, platelet derived growth factor BB (PDGF-BB), is released in 
lesions by endothelial cells, macrophages and SMCs. It has potent proliferative and 
migratory effects on synthetic phenotype SMCs, but little effect on contractile SMCs [37]. 
Proliferation is induced by promoting splicing of histone deacetylase 7 (HDAC7) [38] and 
migration by promoting phosphatidylinositol turnover and calcium signaling [37,39]. 
Prostanoids, a subclass of eicosanoids, are another class of soluble factors with 
roles in atherosclerosis. These include thromboxane, a molecule involved in thrombosis by 
promoting platelet aggregation, and a variety of prostaglandins with effects on 
inflammation, proliferation and platelet aggregation (i.e. prostacyclin I2, prostaglandin E2) 
[40]. However, whether prostaglandin E2 is atheroprotective or promotes atherosclerosis 
is unclear, and its effects are concentration-dependent [41].  
The downregulation of certain atheroprotective compounds, for instance, nitric 
oxide (NO), is also implicated in atherogenesis. NO is normally produced by the 
endothelial cells of the intima, which upregulate expression of endothelial nitric oxide 
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synthase (eNOS) under laminar flow conditions in vitro [42]. This latter observation may 
explain why atherosclerotic plaques are more commonly found near bends, turns and 
bifurcations in the arterial tree [42], where laminar flow is disturbed. NO is known to 
inhibit migration and proliferation of vascular smooth muscle cells in vitro, possibly 
implicating defective NO production in their aberrant behavior during atherosclerosis 
[43,44].  
Transforming growth factor beta (TGFβ) is another factor believed to protect 
against atherosclerosis, possibly through its role in reversing the wound repair process [45]. 
Patients with advanced atherosclerosis have been observed to have reduced serum levels 
of TGFβ [46], but concentrations in plaques are not necessarily altered. Instead, SMCs in 
atherosclerotic lesions in humans are found to have reduced levels of the type II TGFβ 
receptor [45], expression of which is required for functionality of the type I receptor. This 
alteration in the ratio between the type I and II TGFβ receptors with disease and aging may 
explain, in part, the different responses to TGFβ by young and old SMCs and other 
differential, context-dependent effects [47–52].  
Besides these soluble factors, it is becoming increasingly clear that the extracellular 
matrix components in contact with cells can have an impact on disease progression. SMCs 
involved in atherosclerosis must degrade and migrate through basement membrane 
proteins and fibrous collagens and elastin, and it is highly likely that the changing 
environment affects SMC phenotype and behavior. While the basement membrane proteins 
are observed to have protective effects in vitro, the effects of the collagens and other 
proteins are definitely context-dependent.  
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Although the effects of collagen III on SMC phenotype have not been extensively 
studied, it has been reported that fragmentation of collagen III with UV irradiation 
increases proliferation and expression of ICAM-1 and VCAM-1, while simultaneously 
downregulating β1 integrins and the focal adhesion-associated proteins vinculin, talin, and 
the intermediate filament vimentin [53]. The synthesis of collagen III by synthetic 
phenotype SMCs increases when treated with TGFβ, IL-1 or PDGF, however, interferon-
gamma reduces synthesis, even with co-treatment with TGFβ [54].   
Similar to collagen III, monomeric collagen I has been shown to promote 
proliferation and suppress synthesis of extracellular matrix proteins, actin-binding proteins 
and signaling molecules [55,56]. The effects of collagen I on SMCs in vitro is rather similar 
to the effects of collagen III [57], and it is found in abundance in atherosclerotic lesions, 
especially within the SMC-laden fibrous cap [58]. SMCs have been shown to increase 
collagen synthesis in response to many factors commonly found in lesions, especially 
PDGF-BB, endothelin-1, IL-1, homocysteine, TGFβ and mechanical stretch [58]. 
However, despite the typical association of collagen I and III with the synthetic phenotype, 
other studies have found that polymerized or fibrilized collagens can help induce the 
contractile phenotype, in some instances [55,56]. If this effect is relevant in vivo, it is 
presumably reversed when the SMCs are induced to degrade their environment and invade 
a plaque. 
A major extracellular matrix protein found in plaques, fibronectin, is initially laid-
down with fibrin as a provisional matrix during the wound repair response [59]. However, 
since the wound repair process is disrupted in atherosclerosis, the fibronectin deposits are 
not necessarily cleared out and replaced with appropriately-structured collagen fibers. The 
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abundant fibronectin in plaques is believed to help promote the proliferative, synthetic 
phenotype in SMCs, which is supported by in vitro studies [60]. 
The soluble and physical factors discussed above are just a small subset of the 
dozens or hundreds of chemicals and proteins that may have significant effects in the onset 
and progression of atherosclerosis. Not discussed in detail but still of importance are 
molecules such as various proteoglycans (especially chondroitin sulfate and heparan 
sulfates), which have roles in sequestration of growth factors and as co-receptors [61], as 
well as LDL and oxidized LDL particles [7], advanced glycation end products which may 
additionally stiffen plaques [23], and insulin and insulin-like growth factors (but the role 
of IGF-I is debated) [31] that are frequently elevated in patients with atherosclerosis. All 
of these factors and likely many more are important to understanding atherosclerosis, but 
the heterogeneity of plaques suggest that they may not all be important in every instance. 
 
1.2.4 The influence of mechanics in the progression of atherosclerosis 
Given their role in mechanical integrity of the arterial wall, the effects of various 
mechanical stimuli on SMCs is an extensively studied area. As mentioned previously, 
cyclic stretch can promote the contractile SMC phenotype in vitro [19], but it could also 
be implicated in promoting atherosclerosis by inducing production of elastin and collagen 
I [62].  Another effect of blood flow is reflected in how certain portions of the arterial tree 
are prone to plaque development due to low fluid shear stress, which has been found to 
induce downregulation of eNOS in endothelial cells of the intima and thereby reduce 
diffusion of atheroprotective NO to medial SMCs [42]. Disrupted blood flow mechanics 
may have other effects, for instance from transmural interstitial flow due to a damaged, 
12 
 
leaky endothelium, which may potentially contribute to MMP-1 expression and SMC 
migration [63].  
In vitro studies have revealed that differences in static mechanics, typically in the 
form of hydrogels with varying stiffnesses, may also impact SMC phenotype and 
behaviors. On 2D substrates, SMC proliferation tends to increase with substrate modulus, 
but so does expression of contractile phenotype markers, and migration is also modulus-
dependent [64,65]. In 3D cell cultures, migration is reported to be strongly dependent on 
mesh size [66], and once again proliferation and contractile phenotype markers increase 
with modulus [67]. Some of these findings are unintuitive given how atherosclerotic 
plaques tend to stiffen, but other studies find that mesh size is more important than modulus 
[68], and it is very possible that SMC phenotype in atherosclerosis is not as well understood 
as believed.  
 
1.2.5 Late stage complications in atherosclerosis and prevention 
Further complications arise in the late stages of atherosclerosis, especially fibrosis 
and calcification. As discussed above, atherosclerotic plaque composition can vary greatly, 
and in some cases SMCs arranged near the luminal surface of the plaque produce excessive 
amounts of extracellular matrix proteins forming a fibrous cap [7]. Cells in other plaques 
can differentiate into osteoblast-like cells that secrete bone-related proteins including 
osteopontin [69] and calcium salts in the form of hydroxyapatite [70]. Fibrosis and/or 
calcification of plaques can further harden the artery wall, but a stiffer wall may actually 
stabilize the plaque and prevent a deadly rupture event [71,72].  
13 
 
Due to the potentially life-threatening consequences of rupture, much effort has 
been spent on therapies to improve stability [73,74] and on ways of non-invasively 
evaluating stability in at-risk patients [75]. Plaque rupture is a serious complication of 
atherosclerosis that can cause death or brain damage. When a rupture occurs, the 
underlying collagenous tissues are exposed to the blood stream and the coagulation cascade 
is rapidly induced to attempt to patch the rupture with the formation of a clot (thrombosis) 
[7]. However, if the clot embolizes from the site of rupture, the effects are often severe. 
The most common life-threatening consequence of embolism occurs with atherosclerosis 
of the coronary arteries (myocardial infarction), with atherosclerosis of the cerebral arteries 
being the second most common occurrence (stroke). 
Current efforts to treat atherosclerosis focus on prevention through dietary 
intervention and exercise, with an emphasis on low fat foods and ‘heart healthy’ grains. 
However, this view is being increasingly questioned [76–79] in light of considerable 
evidence that low fat diets may actually be more harmful than helpful. In fact, our current 
obesity epidemic began at about the same time the US Senate Select Committee on 
Nutrition and Human Needs issued low fat dietary guidelines in 1977 (Fig. 1.3), and obesity 
is a significant risk factor for atherosclerosis, diabetes, cancer and related diseases.  
Since there has been limited success from dietary interventions, statins have 
become the first line of defense in prevention for patients with pre-existing heart disease, 
or at high risk of developing it. Statins, including the blockbuster drug Lipitor [80], are a 
class of drugs approved for inhibition of 3-hydroxy-3-methyl-glutaryl-Coenzyme A 
reductase (HMG-CoA reductase), a rate-controlling enzyme in the cholesterol synthesis 
pathway [81]; However, statins have since been shown to have other effects that can 
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explain their efficacy, including inhibition of both Rho kinase [82,83] and the uptake of 
oxidized LDL particle [84]. There is also some evidence that statins may be contributing 
to the incidence of dementia in elderly patients [85], but the connection is considered 
tenuous. Statins have been proven effective in reducing the rate of myocardial infarction 
in patients with pre-existing heart disease, but their efficacy at primary prevention was less 
certain until the last couple years [86–89]. There are also surgical options for secondary 
prevention, including stents which mechanically widen an occluded artery [90]. 
Unfortunately, while stent implantation may be life-saving in many cases, the stent itself 
damages the artery wall and induces inflammation and restenosis.    
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Figure 1.3: The current obesity epidemic began around the same time that low-fat dietary 
guidelines were issued by the US Government 
Source: National Center for Health Statistics (US). Health, United States, 2008: With 
Special Feature on the Health of Young Adults. Hyattsville (MD): National Center for 
Health Statistics (US); 2009 Mar. Chartbook. 
 
1.3 Smooth muscle phenotype heterogeneity 
Of note is the phenotypic heterogeneity of SMCs in the arterial wall – they do not 
exist strictly in a ‘contractile’ or ‘synthetic’ phenotype, but rather along a spectrum 
characterized by the expression of certain marker proteins, and are capable of 
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transdifferentiation under the appropriate conditions [91]. The inherent heterogeneity can 
partly be explained by the fact that vascular SMCs are derived from multiple embryonic 
origins, but this is an incomplete explanation [92]. The picture is complicated further by 
observations that, in some cases, a portion of the SMCs present in atherosclerotic plaques 
are actually derived from circulating bone marrow-derived progenitor cells [93], but this is 
controversial [94,95]. It remains likely, however, that the vast majority of the SMCs in 
atherosclerotic plaques originate from the arterial media. 
The marker proteins expressed by contractile SMCs are, not surprisingly, typically 
associated with the actomyosin contractile apparatus, and have roles in regulating 
contractility. With the exception of smoothelin [96], most SMC markers can also be found 
in myofibroblasts in some, but not all, cases, which further supports the idea of a phenotype 
spectrum. The earliest expressed SMC marker, which is also considered the primary 
marker of myofibroblasts, is α-smooth muscle actin (α-SMA), an actin isoform that makes 
up a large portion of the contractile apparatus in smooth muscle. However, α-SMA is a 
necessary, but insufficient marker of the contractile SMC phenotype in vitro due to 
similarities between myofibroblasts and the synthetic SMC phenotype.  
Mid-stage markers of the contractile phenotype include caldesmon, calponin and 
smooth muscle myosin heavy chain (SM-MHC). Caldesmon is an actin-binding protein 
with 2 distinct isoforms, heavy and light (h-CaD and l-CaD), with h-CaD being expressed 
in SMCs and l-CaD in all tissues, including SMCs. In fact, when SMCs dedifferentiate into 
the myofibroblast-like synthetic phenotype in vitro, they convert to predominantly 
expressing the l-CaD isoform. Interestingly, caldesmon is part of the cytoskeleton due to it 
binding and stabilizing actin filaments, but the heavy isoform has additional functionality 
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by inhibiting myosin ATPase activity, giving it a role in the contractile apparatus in smooth 
muscle. This difference may be explained by the only structural difference between the 
light and heavy isoforms, a short, charged spacer linking the actin-binding domain and the 
myosin-binding domain, which could provide the necessary space for interacting with 
myosin in SMCs [97].  
Similarly, calponin is part of both the contractile apparatus and the cytoskeleton, 
with actin-binding and myosin ATPase-inhibiting domains, and 2 major isoforms, basic 
(h1) and acidic (h2) [98]. Like caldesmon, the basic isoform is more strongly expressed in 
smooth muscle cells, and expression is converted upon dedifferentiation to the synthetic 
phenotype. Ironically, calponin itself only has a single calponin homology (CH) domain 
but does not bind actin through this domain, while a doublet of this domain in other proteins 
(e.g. α-actinin and filamin, and many more) is responsible for actin binding [99]. Instead, 
a regulatory domain is responsible for actin binding, while yet another domain interacts 
with and inhibits the ATPase-activity of myosin II. The CH domain enables interaction 
with other contractile proteins like tropomyosin, Ca2+/calmodulin, as well as the signaling 
protein ERK [100]. While calponin itself is not a Ca2+-dependent, as the name would 
suggest, it binds Ca2+/calmodulin, which phosphorylates calponin and inhibits its myosin-
binding activity to modulate contractility [101]. 
Smooth muscle myosin heavy chain is a major functional protein of the contractile 
apparatus, but not a member of the cytoskeleton. It is the smooth muscle-specific isoform 
of the heavy chains of myosin II, with two major splice variants, SM1 and SM2. Non-
muscle cells express non-muscle MHC (NM-MHC), and upon dedifferentiation to the 
synthetic phenotype, SMCs shift expression from SM- to NM-MHC [102]. It is likely that 
18 
 
this smooth muscle-specific isoform is required for interactions with the other smooth 
muscle contractile proteins, like calponin and caldesmon, and these interactions impart 
unique contractile properties to smooth muscle.   
The latest SMC marker recognized, smoothelin, is also purported to be the only 
truly exclusive SMC marker [96]. It has 2 isoforms, a shorter smoothelin-A and longer 
smoothelin-B, which are predominantly found in visceral and vascular smooth muscle, 
respectively [103]. It is an actin binding protein, interacting with filamentous actin through 
CH domains [104], and evidence from knock-out studies in mice points to a role in the 
contractile apparatus [105]. However, the complete function of smoothelin remains 
unknown. 
With the exception of smoothelin-B (and only weakly for smoothelin-A), 
transcription of SMC marker genes is regulated by serum response factor (SRF) and an 
SRF co-activator, myocardin, binding to CArG boxes in contractile marker gene promoters 
[106]. MicroRNAs have garnered attention in cardiac and smooth muscle research in the 
past several years, with the finding they have profound effects on the regulation of cellular 
phenotype. In particular, expression of the microRNAs miR-143 and miR-145 in SMCs is 
induced by myocardin/SRF, forming a positive feedback loop due to the effects of miR-
143/145 on suppressors of myocardin expression or activity; they also suppress non-
myocardin SRF co-activators that would otherwise enable SRF-binding to CArG boxes on 
genes known to promote dedifferentiation to the synthetic phenotype [107]. MicroRNA-1 
is also positively regulated by myocardin [108] and inhibits SMC proliferation, whereas 
the role of microRNA-133 is less certain [109] because it positively affects some SMC 
markers (SM-MHC), but decreases expression of others (calponin, transgelin-2 and α-
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SMA). However, it has an overall positive effect by reducing SMC migration and 
proliferation. One thing is clear: the study of SMC phenotype regulation is extremely 
complex, and it is further complicated and confounded by differences in contexts and even 
the species of cells used in various studies.  
 
1.4 In vivo/animal models 
Researchers have developed several animal models for inducing (or resisting) 
plaque formation reminiscent of that found in humans, most frequently in mice, rabbits and 
rats. These models are very important for corroborating in vitro data and testing potential 
drugs and treatments for reversing or preventing atherosclerosis.  
The earliest work with animal models and atherosclerosis took place primarily in 
Russia in the early 1900’s [110], with a focus on the dietary causes of fatty streak formation 
in rabbits. However, the use of rabbits as an animal model of human atherosclerosis is 
specious, because they are exclusively herbivorous in nature and regulate lipids very 
differently from humans [111].  
In recent years, mice have seen much more frequent use in studies of 
atherosclerosis, especially the apoE-/- knockout mouse. These mice spontaneously forms 
advanced lesions in the aortic root, as well as in other portions of the arterial tree with a 
high cholesterol diet. Other transgenic mice have been developed as models dyslipidemia 
(the SR-BI knockout), familial hypercholesterolemia (the LDLR-/- mouse), and for features 
of metabolic syndrome (db/db, ob/ob mice) [111].  
Other less-frequently used animal models include rats and hamsters, and the difficult-
to-use nonhuman primates and pigs. Rats are, however, frequently used in a balloon injury 
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model of restenosis, a pathological process with many similarities to atherosclerosis 
[112,113]. Certain primates (e.g. chimpanzees, rhesus monkeys) and pigs are possibly the 
ideal animal models for human atherosclerosis, owing to their similar diets, circulatory 
systems and lipid regulation. Unfortunately, they are also large, expensive to care for, have 
long lifespans and time to maturation, and their use in biomedical research is ethically 
challenging.  
 
1.5 In vitro models 
There are numerous reports of in vitro model systems designed to mimic one or 
more features of the vasculature. These models are used to investigate SMC phenotype and 
behaviors, including proliferation and migration in response to growth factors and ECM 
proteins, and the expression of contractile SMC markers. To reflect the in vivo reality, SMC 
differentiation is reported to be enhanced by coculture with endothelial cells [114–116], 
which most likely induces differentiation and quiescence due the secretion of soluble 
factors by endothelial cells, most prominently, NO. In order to model changes with arterial 
stiffness with aging and disease, several groups have used mechanically-tunable hydrogels 
[64,67,68,117–122]. These reports investigate static mechanical effects on proliferation 
and cell area, which are positively affected, as well as 2D and 3D migration, and marker 
expression. Another group has reported that culturing SMCs on an NO-generating 
polymeric biomaterial [123] reduces proliferation, which recapitulates some features of 
SMC/endothelial cell coculture.  
There have also been numerous reports on more mechanically complex model 
systems. For instance, the application of cyclic stretch or strain is used as a model of the 
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mechanical environment produced by pulsatile blood flow [19,62,119,124,125], and 
various SMC behaviors are reportedly affected, including secretion of ECM proteins and 
cytokines, proliferation, and cell shape. However, there is disagreement in these literature 
reports on whether or not cyclic strain is beneficial to SMC phenotype, which is likely a 
consequence of the specific contexts studied. Other systems model the effects of a 
damaged, leaky vascular endothelium on the pathogenesis of atherosclerosis by inducing 
interstitial fluid flow through SMCs encapsulated in collagen I gels [126–129], with 
findings of significant effects on SMC expression and secretion of MMPs, leading to 
subsequent degradation and invasion of the collagen gel matrix.  
 
1.6 Mechanotransduction 
Generally, cells are able to sense their mechanical environment predominantly 
through integrin-linked focal adhesion structures [130]. These structures are formed on the 
cytoplasmic side of integrin clusters and involve dozens of scaffolding and signaling 
proteins. Cells are able to mechanosense through focal adhesions due to the presence of 
so-called mechanosensitive proteins such as talin [131]. These proteins are 
mechanosensitive because they are tethered to both the membrane-anchored adhesion as 
well as actin stress fibers and, as actomyosin contraction pulls on the adhesions, the 
proteins are physically unraveled, exposing binding sites for various signaling molecules 
[131]. Typically, cells seemed to try to balance the internal cytoskeletal tension with the 
tension at integrin-ECM connections [132], and so a stiffer substrate will result in greater 
contraction and pull those proteins open to expose signal protein binding sites. For these 
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reasons, substrate modulus is a major factor that should be controlled in cell biology 
experiments.  
 
1.7 Hydrogels for studying mechanobiology 
As in atherosclerosis, a wide variety of diseases, tissues and individual cell types 
are affected by mechanical cues from the microenvironment. Mechanical stimuli, which 
may include tissue modulus, shear stress, and cyclic stretch, are documented to influence 
cell migration [64,65,133], differentiation [67,134,135], proliferation [136], and other 
events [137]. The study of mechanobiology benefits from the development of mechanically 
tunable biomaterials for in vitro cell experiments. The biomaterials most commonly used 
are hydrogels, including synthetic polymers, such as polyacrylamide (PAA) [120,138,139], 
and poly(ethylene glycol) (PEG) [67], and biologically derived gels, such as alginate [140], 
MatrigelTM [141], fibrin [142], and type I collagen [143]. Of these, biological hydrogels are 
the easiest to adapt, as they are commercially available, and inherently contain the integrin-
binding and proteolytic domains cells encounter in vivo. However, increasing the 
concentrations of these proteins in order to increase the gel modulus also increases the 
density of integrin-binding domains, decreases the porosity, and alters degradability [144]. 
These parameters cannot be easily decoupled, making it difficult to determine which ECM 
property most significantly affects cell behavior. PAA was the first popularized synthetic 
hydrogel for cellular mechanobiology [139], in part because one can independently tune 
the integrin-binding and bulk modulus. However, it is not entirely resistant to protein 
adsorption [145], and cannot be used to study three dimensional (3D) cell behavior.  
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PEG-based gels are inexpensive, have independently tunable integrin-binding, bulk 
modulus, and proteolytic domains [117,146,147], and can be used to study cell behavior in 
3D with appropriate modifications [148–150].  However, the mechanical range of PEG-
based gels is limited, typically in the range of 0.5-5 kPa when crosslinked with 
proteolytically degradable groups [67], or 20-500 kPa with diacrylate or dimethacrylate 
free radical crosslinking [117,151].  PEG and PAA-based hydrogels have been used 
extensively to study mechanobiology, for example to demonstrate that cells sense the 
rigidity of their substrate and respond dynamically to changes in tension [133], or that 
substrate modulus affects stem cell lineage specification [134]. 
 
1.8 Hypothesis 
 To date, biomedical research has generally taken a reductionist approach and used 
simple in vitro models, and in vivo animal models that are often of questionable relevance 
to human physiology and disease. The primary aim of this dissertation work is to begin to 
bridge the gap between these types of studies by designing a complex in vitro model that 
captures several major features of the in vivo vasculature to study SMC phenotype in the 
context of atherosclerosis. Of course, this approach relies completely on the foundational 
work of the studies that precede it, and thus those works are absolutely critical despite any 
shortcomings they may have. The expectation is that piecing together that information to 
more closely match the in vivo microenvironment will reveal interactions, phenotypes, and 
behaviors that may be unobtainable with the simpler models. Prior works are also essential 
in helping us understand, interpret, and corroborate the data and observations from a more 
complex model. Altogether, the fundamental hypothesis of this dissertation is that, with 
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previous works as a guide, we can design a complex in vitro model that recapitulates crucial 
elements of the in vivo cellular microenvironment to reproduce physiologically-relevant 
phenomena in vitro. Finally, these phenomena can be examined in depth to parse the 
integration of physical, mechanical, and chemical signals and reveal potential regulatory 
pathways and pathway interactions that may not otherwise be observed in simpler in vitro 
models, and with this new information seek novel drug targets and therapies.  
 
1.9 Objectives for Dissertation 
 To test the hypothesis proposed in the prior section, I set forth the following 
objectives for this dissertation work: 
1. Design and characterize a superior hydrogel to study mechanobiology, with 
features: 
a. Non-fouling 
b. Can be made very soft or stiff, within a physiologically relevant range 
c. Inexpensive, simple to make 
d. Supports attachment of full-length proteins 
e. Optically transparent 
2. Demonstrate that the hydrogel is appropriate for cell culture studies, with 
requirements: 
a. Cells must be able to ‘feel’ differences in modulus/stiffness 
b. Must demonstrate that stiffness can affect cell behavior 
3. Design a complex in vitro model for SMC phenotype, with features: 
a. ECM proteins commonly associated with intact vascular media and with 
the atherosclerotic plaque. 
b. Soluble factors reported relevant to atherosclerosis or maintenance of 
SMC phenotype. 
c. Soft and stiff substrates to simulate the stiffening and fibrosis frequently 
associated with the development of plaques. 
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4. Use this in vitro model to parse the effects of the model features on relevant SMC 
phenotypes: 
a. Marker expression 
b. Proliferation 
c. Migration 
d. Invasion 
5. Finally, probe signaling pathways predicted to be involved in these behaviors, 
with a focus on integrins, soluble factors, and how they activate interacting 
signaling pathways. 
 
 
1.10 Significance 
While there are certainly studies that use relatively complex in vitro model systems, 
the majority of biomedical research is performed on glass or polystyrene, and the effects 
of extracellular matrix proteins and other mechanical effects are often neglected. This 
approach has led to a huge amount of disagreement within the literature, and the vast 
majority of potential therapeutics or treatments that are successfully tested in animal 
models sadly do not translate to humans. We believe that the valuable information gained 
from these studies, however, can be used to design increasingly complex in vitro models 
that may vastly improve the odds of making discoveries that are directly applicable to 
human health and disease. The aim of this dissertation work was to apply this approach to 
the study of SMC phenotype in the context of atherosclerosis. Through the course of this 
dissertation research, we have developed and characterized an exceptional synthetic 
hydrogel for mechanobiology research. We then used this hydrogel platform to study the 
effect of substrate modulus on the proliferation and mechanotransduction properties of 
three cancer cell types, the first ever mechanobiology report of this type with these cells. 
Once proven suitable, we then used this hydrogel as one element of complexity in in vitro 
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models of the vascular microenvironment. Along with this static mechanical feature, we 
also introduced two mixtures of healthy- and disease-associated ECM proteins and 2 
medium supplements containing soluble factors associated with the healthy and disease 
states. By recapitulating several elements of in vivo complexity, we have recreated 
physiologically-relevant behaviors in vitro and provide evidence to reconcile some 
disputes in the literature and dispute some widely-held notions regarding SMC phenotype. 
We also propose a detailed, literature-supported hypothetical mechanism by which ECM 
binding controls SMC behaviors, with potentially widespread implications in many other 
areas, including cancer. While additional work will be required before we can fully 
understand these results and confirm our proposed mechanisms, we believe this work will 
be of great interest to any investigators interested in SMC phenotype and the role of the 
microenvironment on disease states and cell behaviors.  
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CHAPTER 2 
PEG-PC SYNTHESIS AND MECHANICAL PROPERTIES 
 
2.1 Abstract 
 This chapter will detail the development, synthesis and mechanical characterization 
of a novel hydrogel with significant utility in mechanobiology and disease research. The 
goal of this work was to create a novel, tunable hydrogel with exceptional anti-fouling 
properties to control the type and presentation of extracellular matrix proteins. This was 
achieved by copolymerizing the well-characterized PEG-dimethacrylate hydrogel with a 
methacrylated phosphorylcholine (PC) monomer. Phosphorylcholine was chosen because 
it is a very hydrophilic zwitterion, which imparts the ability to resist protein fouling. We 
find that free radical-copolymerized PEG and PC (‘PEG-PC’) has a mechanical range of 1 
kPa to 10 MPa Young’s modulus, which matches or exceeds any previously reported 
hydrogel, and average mesh sizes that are smaller than typical growth factors or other 
soluble factors (≤ 5 nm). PEG-PC also has reduced fouling compared to PEG itself, which 
we show is [PC]-dependent. Finally, we characterize the optical clarity of PEG-PC on 
coverslips and find that it is completely transparent from approximately 1 kPa to 1 MPa 
Young’s modulus. 
 
2.2 Introduction 
The development of tunable biomaterials has driven rapid progress in tissue 
engineering, either to facilitate or enhance the natural wound healing process, or to act as 
functional replacement tissues in the human body.  Biomaterial platforms have been 
developed both for eventual in vivo application, as well as for in vitro model systems for 
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studying complex biological processes, including cell migration, adhesion, proliferation, 
and differentiation.  Information from these in vitro studies drives the design of implantable 
scaffolds, and promotes understanding of complex biology in environments more 
physiologically relevant than traditional plastic and glass surfaces.  Studying cellular 
phenomenology and signaling mechanisms in microenvironments that capture key features 
of the in vivo extracellular matrix (ECM) is more efficient and cost-effective than animal 
studies, and may prove to be more predictive of human clinical outcome.   
Mechanical cues from materials and the microenvironment, such as substrate 
modulus, shear stress, and stretch, influence cell migration [1–3], differentiation [4–6], and 
proliferation [7] (for review, see ref. [8]). Mechanotransduction, the translation of a 
mechanical cue from the ECM into a biochemical one, is mediated by focal adhesions [9]. 
There have been many studies on the effects of substrate modulus on cell spreading [1,10–
16], focal adhesion properties [1,11,15,17], proliferation [4,6,11,18–20], migration [1–
3,21,22], and phenotype and differentiation [4,5,20,23–25] with several materials 
platforms [1,12–14,18,20,26–29]. Materials most commonly used to investigate 
mechanobiology are hydrogels, including synthetic polymers, such as polyacrylamide 
(PAA) [30–32], and poly(ethylene glycol) (PEG) [4], and biologically derived gels, such 
as alginate [33], MatrigelTM [34], fibrin [35], hyaluronic acid [14,20,29] and type I collagen 
[36]. Of these, biological hydrogels are the easiest to adapt, as they are commercially 
available, and inherently contain the integrin-binding and proteolytic domains cells 
naturally encounter in vivo. However, manipulating the concentrations of these proteins in 
order to control the gel modulus simultaneously alters the density of integrin-binding 
domains, porosity, and degradability [22]. These parameters cannot be decoupled easily, 
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making it difficult to determine which ECM property most significantly affects cell 
behavior.  
With respect to synthetic hydrogels, PAA was the first popularized platform for 
cellular mechanobiology [32], in part because it was the first system to demonstrate 
independent tuning of cell adhesion and modulus.   While PAA is an important material, it 
has limitations, such as a narrow mechanical range, and it is not suitable for three-
dimensional (3D) studies. PEG-based gels are inexpensive, have independently tunable cell 
adhesion, bulk modulus, and proteolytic domains [11,37,38], and can be used to study cell 
behavior in 3D [39–41]. However, the mechanical range of PEG-based gels is limited, 
typically in the range of 0.5-5 kPa when crosslinked with proteolytically degradable groups 
[4], or 20-500 kPa with diacrylate or dimethacrylate crosslinking [11,42]. We sought to 
improve on this limited range of Young’s moduli, by combining the commonly used 
PEGDMA crosslinker with an inexpensive, extremely hydrophilic zwitterion.  We report 
here the synthesis of a hybrid polymer hydrogel, which combines PEG-dimethacrylate 
(PEGDMA), with the zwitterionic comonomer 2-methacryloyloxyethyl phosphorylcholine 
(PC).  To our knowledge, these “PEG-PC” hydrogels have a mechanical range that matches 
or exceeds any previously reported hydrogel system, and, importantly, they are simple, 
inexpensive to produce, and retain optical clarity over most of their mechanical range. 
 
2.3 Materials & methods 
2.3.1 Synthesis of PEG-PC hydrogels 
In most cases, PEG-PC polymer hydrogel precursor solutions were prepared by 
mixing PEGDMA (average Mn 750, Sigma-Aldrich, St. Louis, MO), varied between final 
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concentrations of 7.4 mM and 0.7 M (0.5-55 wt.%, see Figure 2.2E), and 0.6 M (17 wt.%) 
2-methacryloyloxyethyl phosphorylcholine (MPC; Sigma-Aldrich) in phosphate buffered 
saline (PBS). Solutions were degassed for 30 seconds with nitrogen, and sterilized with a 
0.2 µm syringe filter (Thermo Fisher Scientific, Waltham, MA). Depending on the desired 
format, we have used two different free radical initiators for polymerization.  To cure under 
UV light, 0.8 wt.% Irgacure 2959 (from a 20 wt.% stock in 70% ethanol; BASF, 
Ludwigshafen, Germany) was added, and gel formation was induced with a Spectroline 
High-Intensity UV Lamp with 365 nm light (Model #SB-100P, Westbury, NY), at 
approximately 3.5 inches from the gel for 7 minutes. To polymerize hydrogels without UV 
light, we added 0.05 wt.% ammonium persulfate (APS, from a 20 wt.% stock in water; 
Bio-Rad Laboratories, Hercules, CA) and 0.125 vol.% tetramethylethylenediamine 
(TEMED, Bio-Rad Laboratories) and polymerized gels under nitrogen for 10 minutes.  
We also performed some experiments with different concentrations of MPC: 1) for 
mechanical testing, we UV polymerized hydrogels with MPC:PEGDMA molar ratios of 
13.9, 7.23 and 2.59 at a constant 20.4 wt.% total polymer (600/43.1, 510/70.5 and 348/135 
mM MPC/PEGDMA, respectively), and 2) for comparison of swelling and mechanical 
properties between molecular weight-matched MPC and a PEG-methacrylate (PEGMA) 
comonomers, we UV polymerized hydrogels with constant [PEGDMA] (135 mM) and 
concentrations of MPC or PEGMA of approximately 160, 300 and 600 mM. Due to the 
poor solubility of PEGMA in water, these latter hydrogels were polymerized in 70% 
ethanol. 
To make thin PEG-PC hydrogels with even heights suitable for microscopy, 75 µL 
aliquots of PEG-PC solution was cured between chemically modified 18 mm glass 
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coverslips. Methacrylate silanized coverslips served as the base, and covalently attached to 
the hydrogel during polymerization, whereas hydrophobic coverslips could be easily 
removed from the final, hydrophilic hydrogels.  To create the methacrylate coverslips, slips 
were treated with O2 plasma for 10 minutes, reacted in 200 mL of 95% ethanol with 2 
vol.% 3-(trimethoxysilyl) propyl methacrylate (adjusted to pH 5.0 with glacial acetic acid; 
Thermo Fisher Scientific) for 2 minutes with shaking, washed three times in 200 proof 
ethanol, and finally dried at 120°C for 15 minutes[43]. Hydrophobic coverslips were made 
with coverslips submerged in Sigmacote (Sigma-Aldrich), shaken for 20 minutes, washed 
3 times with 200 proof ethanol, and dried under vacuum.  Following polymerization, the 
Sigmacote cover slips were removed from the gel surface with fine forceps, and the gels 
were allowed to swell in sterile PBS for 24 hours. Prepared coverslips were stored in foil 
in a desiccator at room temperature. 
To synthesize PEG-PC hydrogels for high throughput applications, 96-well 
microplates with glass bottoms (no. 1.5 coverslip glass; In Vitro Scientific, Sunnyvale, CA) 
were treated with O2 plasma for 10 minutes, reacted with 100 µL/well of 2 vol.% 3-
(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich) in 95% ethanol (to pH 5.0 with 
glacial acetic acid; Thermo Fisher Scientific) for 2 minutes, with shaking, then rinsed 3x 
with 200 proof ethanol, and dried at 40°C for 30 minutes. To polymerize hydrogels in 
wells, pre-polymer solutions were prepared with APS and TEMED polymerization as 
described above, and added to the 96-well plate at 40 µL/well. To remove O2 in the air that 
would inhibit polymerization, plates were placed in a vacuum oven at room temperature, 
pure N2 gas flushed through the chamber for 5 minutes, and then the chamber sealed for 
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10 minutes to complete the reaction. Finally, hydrogels were swelled overnight with 100 
µL/well PBS.    
 
2.3.2 Hydrogel mechanical and structural characterization 
PEG-PC hydrogel cylinders for mechanical compression testing were formed in 
Teflon molds (5 mm height, 5.5 mm diameter) and swelled in PBS for 48 hours. Post-
swelling, hydrogel dimensions were measured with digital calipers, and mechanical 
compression tests were performed with a TA Instruments (New Castle, DE) AR-2000 
rheometer using a 2 µm/second strain rate. The Young’s modulus (E) for each hydrogel 
was calculated by plotting the measured normal force between 0 and 4% strain, and 
dividing the slope of the best-fit linear regression by the hydrogel cross-sectional area (see 
Fig. 2.1 for a representative stress-strain curve and example calculation). The Young’s 
modulus was calculated from ≥ 4 samples at each PEGDMA concentration. 
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Figure 2.1: Young’s modulus example calculation 
Young’s moduli were calculated by uniaxially compressing a cylindrical hydrogel and 
plotting the measured normal force versus strain from 0 to 4%. The modulus is then 
computed as the slope of the stress-strain curve divided by the cross sectional area of the 
hydrogel cylinder. 
 
To determine an approximate average mesh size as a function of PEGDMA 
crosslinker content with constant PC content, hydrogels were swelled in PBS for 48 hours 
then weighed, fully lyophilized under vacuum and moderate heating, and weighed again. 
The average mesh sizes, 𝜉, of the PEG-PC hydrogels were determined as a function of 
PEGDMA crosslinker concentration according to the Flory theory, as modified by Canal 
and Peppas [44]: 
𝜉 = υ2,s
−
1
3(r̅2)1/2 
where υ2,s is the swollen volume fraction of polymer and (r̅
2)1/2 is the average end-to-end 
distance of the PEGDMA crosslinker. 
To detect unreacted methacrylate groups, NMR was performed on PEG-PC 
samples polymerized with APS and TEMED in microcentrifuge tubes with a Bruker 
Spectrospin DPX300 (Bruker Corporation, Billerica, MA). D2O was used as the solvent. 
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To quantitatively measure the observed transparency of PEG-PC versus PEGDMA, 
hydrogels were made on cover slips, as described above, from 135 mM to 0.7 M PEGDMA 
with and without 0.6 M PC. After 48 hours of swelling in PBS, the optical densities of 
hydrogels in clean PBS were measured at 450, 490, 572, 630 and 750 nm with a BioTek 
ELx800 absorbance microplate reader (BioTek, Winooski, VT). 
   
2.3.3 Quantification of non-specific protein adsorption 
We quantified protein adsorption to the hydrogels with an indirect ELISA [45]. 
Hydrogels were polymerized in 96-well plates, swelled in PBS overnight, and incubated 
with 10 mg/mL bovine serum albumin (BSA; Sigma-Aldrich) for 20 hours at 37°C. The 
gels were washed 5x with PBS, incubated with primary antibody to BSA (Life 
Technologies, Carlsbad, CA) in PBS for 90 minutes, washed again 5x with PBS, and 
incubated with secondary antibody conjugated to horseradish peroxidase (HRP; Abcam, 
Cambridge, UK) for 90 minutes. After washing 5x with PBS, the gels were incubated with 
0.1 mg/mL 3,3’,5,5’-tetramethylbenzidine (TMB; Sigma-Aldrich) and 0.06% hydrogen 
peroxide (Thermo Fisher Scientific) in 0.1 M sodium acetate (pH 5.5; Sigma-Aldrich) for 
1 hour at room temperature with shaking. At 1 hour, an equal volume of 1 M sulfuric acid 
(Sigma-Aldrich) was added to each well, and the absorbance at 450 nm was measured with 
a BioTek ELx800 absorbance microplate reader (BioTek). 
 
2.3.4 Statistical analysis 
Statistical analysis was performed using Prism v5.04 (GraphPad Software, La Jolla, 
CA).  Data are reported as mean ± standard deviation, unless otherwise noted.  Statistical 
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significance of the difference between pairs of means was evaluated by computing P-values 
with unpaired Student's t-tests (with Welch's correction as necessary). P ≤ 0.05 is denoted 
with *, ≤ 0.01 with **, ≤ 0.001 with *** and ≤ 0.0001 with ****; P > 0.05 is considered 
not significant ('ns'). 
 
2.4 Results 
2.4.1 PEG-PC hydrogels are mechanically tunable over a wide range of Young’s 
moduli 
We synthesized hydrogels from varying concentrations of PEGDMA with constant 
PC, and characterized physical properties important for a viable cell culture platform (Fig. 
2.2).  We quantified the Young's moduli of photopolymerized PEG-PC hydrogels with 0.6 
M PC (20 wt.%) in PBS and PEGDMA ranging from 7.4 to 700 mM (0.5 – 55 wt.%) via 
compression testing (Fig. 2.1, 2.2B). As expected, we found that hydrogel modulus 
increases with crosslinker concentration from 0.9 ± 0.2 kPa at 7.4 mM PEGDMA to 9300 
± 900 kPa at 0.7 M PEGDMA. This mechanical characterization demonstrates a tunable 
range of Young’s moduli that spans four orders of magnitude, from 900 Pa to nearly 10 
MPa.  We attribute this wide range of moduli to the inclusion of the PC zwitterion, enabling 
gelation at very low concentrations of PEGDMA (7.4 mM, or 0.5 wt.%). This range of 
Young’s moduli spans the reported moduli of nearly any tissue type, including brain, tumor 
tissue, skin, cartilage, and some areas of bone[46]. 
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Figure 2.2: PEG-PC hydrogels are mechanically tunable over four orders of magnitude 
(a) Schematic of PEG-PC hydrogel structure, which were prepared by free-radical 
polymerization to form PEGDMA-crosslinked linear PC polymers that entangle and form 
gels at very low [PEGDMA] concentrations. At very high [PEGDMA], the network 
structure is dominated by PEGDMA with sparsely distributed PCs. (b) Young’s modulus, 
E, of PEG-PC hydrogels as a function of [PEGDMA] from 7.4 mM to 0.7 M.  PC is 20 
wt.% (0.6 M). Error bars are SDs. Each adjacent pair is significantly different with p < 
0.001 or better. (c) PEG-PC swelling behavior in PBS, which is maintained even at very 
high [PEGDMA]. (d) The average mesh sizes of PEG-PC hydrogels (PC at 0.6 M) as a 
function of [PEGDMA]. Error bars are SDs (N ≥ 4). (e) Table detailing all mechanical 
testing results.  
 
In a single-polymer hydrogel, mesh size and modulus are generally coupled with 
the total polymer mass fraction. Due to the interesting 2-regime effects we have observed, 
we also examined the effect on Young’s modulus of the molar ratio of [PEGDMA]:[PC] 
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in hydrogels with constant total polymer fraction (Fig. 2.3). We find that the Young’s 
modulus is linearly and positively associated with [PEGDMA], but negatively associated 
with [PC] (R2 = 0.9997 and 0.9979, respectively; data not shown), and the ratio of 
[PEGDMA]:[PC] is positively and linearly associated (R2 = 0.9873). This result may be 
explained by 2 mechanisms (or a combination of both): 1) as PC content increases, so does 
swelling (to be discussed further, below), which results in larger mesh sizes and lower 
moduli, or 2) increasing PEGDMA increases the number of reactable groups, which creates 
a more tightly crosslinked polymer network with smaller mesh sizes and higher moduli. 
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Figure 2.3: The effect of varying [PEGDMA]:[PC] with constant polymer fraction 
PEG-PC gels with varied ratios of PEGDMA:PC and constant polymer mass fraction were 
polymerized and tested with mechanical compression. We find a positive and linear 
association (R2 = 0.9873) with Young’s modulus and [PEGDMA]:[PC] that is likely due 
to a combination of the effects of PC on swelling and PEGDMA on crosslinking density. 
 
In the mechanobiology field, laboratories typically use either APS and TEMED, or 
Irgacure, as free-radical initiators of hydrogel polymerization. We observed minor 
differences in Young’s modulus when comparing hydrogels made with one of these two 
initiators at the same PEGDMA concentration (Fig. 2.4). The Young's modulus of PEG-
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PC hydrogels at 0.6 M PC and 7.4 mM PEGDMA polymerized with APS was 5.9 kPa, 
compared to 900 Pa when polymerized with Irgacure. This trend was consistent at low 
concentrations of PEGDMA, but differences diminish with increasing PEGDMA content. 
The mesh size with these same conditions are 4.1 ± 0.1 and 5.3 ± 0.4 nm, respectively. 
These data indicate that the differences in properties at low [PEGDMA] are likely due to 
differences in reaction rate or efficiency between the two free radical initiators.  
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Figure 2.4: Free radical initiator affects PEG-PC modulus at low [PEGDMA] 
PEG-PC cylinders of varying [PEGDMA] were polymerized with APS and TEMED and 
the Young’s modulus determined from mechanical compression testing. The difference in 
hydrogel modulus between polymerization with Irgacure (IRG) and APS/TEMED (APS) 
narrows as [PEGDMA] increases, likely due to differences in reaction rate or efficiency. 
Figure adapted with permission from [47], Copyright © 2013 American Chemical Society. 
 
2.4.2 PEG-PC hydrogels have small mesh sizes and structure-dependent swelling 
properties 
The average mesh sizes (𝜉) of PEG-PC hydrogels from 7.4 mM to 0.7 M PEGDMA 
ranged from 5.3 ± 0.4 nm at 7.4 mM crosslinker to 0.95 ± 0.01 nm at 0.7 M crosslinker 
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(Fig. 2.2D). These sizes approximate values reported for other common synthetic 
hydrogels such as PEG-diacrylate (𝜉 ~ 1.4 - 7 nm) [48], poly(vinyl alcohol) (𝜉 ~ 4 - 32 nm) 
[44], or poly(2-hydroxyethyl methacrylate) (𝜉 ~ 1.6 - 2.4 nm) [44]. Significantly, all but 
the softest PEG-PC has mesh sizes smaller than the predicted hydrodynamic radius of 
common growth factors, such as FGF-1 and -2, PDGF-BB, EGF and TGFβ1 (Rhyd ~4.4 – 
5.1 nm, predicted from light scattering data and molecular weights [49]), which we expect 
will prevent their artificial sequestration in the substrate. While the mesh size of 135 mM 
PEGDMA hydrogels is only 0.5-fold higher than 135 mM PEG-PC (3.2 nm vs 1.8 nm, 
respectively), the Young's modulus is 10-fold lower (55 kPa vs 500 kPa, respectively [50]), 
demonstrating the profound effect of the methacrylic PC polymers on the hydrogel 
mechanical properties, and their impact on the overall gel volume fraction. 
Interestingly, the expected strong correlation between mesh size and Young’s 
modulus was found only over a partial range of crosslinker concentrations (Fig. 2.2B, D). 
There were two different regimes where mesh size and Young’s modulus strongly 
correlated: from 7.4 to 135 mM PEGDMA (Pearson’s R = -0.8383, p < 0.05), and from 0.3 
to 0.7 M PEGDMA (Pearson’s R = -0.9572, p < 0.05). Interestingly, these behaviors 
separate where the weight fraction of PC and PEGDMA are equal in the gel. This finding 
suggests a change in the fundamental structure of the hydrogel, from one dominated by a 
PEGDMA-crosslinked methacrylic PC polymer to one dominated by a PEGDMA-
crosslinked PEG polymer with sparsely distributed PC pendants (Fig. 2.2A). To investigate 
whether these regime changes were due to incomplete methacrylate conversion, we 
collected NMR spectra on the PEG-PC hydrogels. These spectra (Fig. 2.5) indicate 
complete methacrylate conversion for PEG-PC hydrogels up to 0.4 M PEGDMA. While it 
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is not possible to directly quantify the methacrylate conversion from these spectra, the post-
swelling dry gel masses for these gels are 99% or more of the theoretical polymer masses 
(data not shown), implying that methacrylate conversion is very high at all concentrations 
of PEG. 
 
Figure 2.5: NMR spectra of PEG-PC hydrogels 
1H NMR spectra of 5 hydrogel samples prepared with varying concentrations of PEGDMA 
crosslinker.  As PEGDMA, and presumably the crosslink density increases, some residual 
monomer is noted at 5.5 and 6.0 ppm (vinyl protons). Figure adapted with permission from 
[47], Copyright © 2013 American Chemical Society. 
 
Given the very high moduli and small mesh sizes of highly crosslinked PEG-PC 
hydrogels, we speculated that these gels may not swell water typical of PEG gels. 
Surprisingly, from swelling data, we ascertained that PEG-PC does in fact swell PBS at all 
crosslinker concentrations (Fig. 2.2C), and we again observed two different regimes of 
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swelling behavior, separated at the point where the gels undergo a change between a PC 
and PEG-dominated structure. In examining the stress-strain curves from compression 
testing, we found that the hydrogels behaved as linear elastic gels at low strain in PC-
dominated networks, and non-linearity was observed above this regime change (Fig. 2.6). 
Recent studies have implied that cells may be able to sense these types of differences in 
network structure [51]. In contrast to these studies, however, we observed non-linearity at 
only the highest moduli, outside the mechanical range reported to be discernable by most 
cell types (E ≤ 500 kPa). 
 
Figure 2.6: PEG-PC hydrogels are linearly elastic up to 0.3 M PEGDMA 
At low strain, PEG-PC behaves as a linearly elastic material in the PC-dominated regime 
([PEGDMA] < 0.3 M), but in the PEGDMA-dominated regime the stress-strain curves are 
slightly nonlinear. There is evidence that cells feel nonlinear elastic materials differently 
than linear elastic materials, but the mechanical range of PEG-PC (up to 500 kPa) that is 
linear elastic covers the vast majority of tissue types. Figure adapted with permission from 
[47], Copyright © 2013 American Chemical Society. 
 We also compared the effect of PC on swelling properties with a weight-matched, 
non-zwitterionic methacrylated comonomer, PEGMA (MN ~ 300) with constant 
[PEGDMA]. These results (Fig. 2.7), presented here as the percent increase in swelling 
with PC compared to PEGMA, show a linear relationship (R2 = 0.9746) between 
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comonomer concentration and increased swelling. These data further support the theory 
that hydrophilic PC groups enhance hydrogel swelling and thereby enable the incredible 
range of mechanical properties we have reported with PEG-PC. 
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Figure 2.7: Swelling is enhanced by PC comonomer 
The role of PC on PEG-PC swelling properties was investigated by comparing against a 
non-zwitterionic, methacrylated comonomer of similar molecular weight, PEGMA, with 
varying concentrations and constant [PEGDMA]. The PC-induced increase in swelling 
over PEGMA linearly increases with comonomer concentration, confirming that PC 
groups in the hydrogel increase swelling, presumably because of their zwitterionic 
structure and hydrophilicity. 
 
2.4.3 PC groups reduce non-specific protein adsorption to PEG gels 
PEG is an amphiphilic polymer that is resistant to non-specific protein adsorption. 
We hypothesized that incorporation of extremely hydrophilic PC groups would further 
enhance resistance to protein adsorption. We tested this by adsorbing BSA to PEGDMA 
(0.145 M) and PEG-PC (0.6 M PC, 0.054 M PEGDMA) hydrogels that had the same 
Young’s modulus, and, after extensive washing, measuring the adsorbed protein with an 
indirect ELISA. As expected, the PEGDMA hydrogels had small, but detectable levels of 
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BSA on the surface, whereas no BSA was detectable on PEG-PC surfaces (Fig. 2.8A), nor 
on polyacrylamide gels (data not shown).  
We also quantified the effect of PC content in hydrogels on protein adsorption by 
measuring BSA adsorption on hydrogels with constant PEGDMA (0.084 M) and varied 
PC concentration (0.15, 0.3 and 0.6 M). As expected, BSA levels decreased with increasing 
PC content (Fig. 2.8B), with half the signal at 0.6 M PC as at 0.15 M. Interestingly, BSA 
was detected on PEG-PC hydrogels with 0.084 M PEGDMA, but not on the hydrogels with 
0.054 M PEGDMA. This suggests that adsorption increases when the ratio of 
PEGDMA:PC increases, further supporting our hypothesis that PC groups decrease non-
specific protein adsorption. 
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Figure 2.8: PEG-PC hydrogels are non-fouling, and optically transparent at low 
PEGDMA concentrations 
(a) Comparison of adsorption of BSA to modulus-matched PEGDMA (0.145 M) and PEG-
PC (0.6 M PC and 0.054 M PEGDMA) hydrogels measured by ELISA with TMB as 
detection substrate. No BSA was detected (compared to negative controls) on the PEG-PC 
hydrogel. (b) Adsorbed BSA was measured as a function of PC concentration with constant 
[PEGDMA] (0.084 M). Adsorption decreases with increasing PC content, demonstrating 
the ability of PC to prevent fouling. (c) The optical density of PEG-PC (left) and PEGDMA 
(right) hydrogels on coverslips in PBS was measured at several wavelengths. The optical 
density of PEG-PC hydrogels are lower than PEGDMA hydrogels at 135 mM and 0.3 M, 
but the opposite is true at 0.5 and 0.7 M. Error bars are standard deviations (N ≥ 2). (d) 
Visual comparison of the optical transparencies of PEG and PEG-PC hydrogels at 0.135, 
0.3, 0.5 and 0.7 M PEGDMA. PEG-PC hydrogels are 0.6 M PC. Figure adapted with 
permission from [47], Copyright © 2013 American Chemical Society. 
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2.4.4 PEG-PC hydrogels are optically transparent 
For a hydrogel platform to be particularly useful for microscopy, the optical clarity 
(and refractive index) would ideally be close to that of glass or plastic substrates. Both PEG 
and PAA hydrogels become opaque at high crosslinker concentrations.  These PEG-PC 
hydrogels are completely transparent at all but the very highest cross-linker concentrations 
of (Fig. 2.8C, D), with opacity emerging when the PEGDMA content reaches 40 wt.%.  
Optical properties were characterized after polymerizing hydrogels on coverslips, then 
measuring optical density (OD) at several different wavelengths (Fig. 2.8C). PEG-PC 
hydrogels are completely transparent (having ODs equal to the polystyrene surface) across 
all wavelengths up to 0.3 M PEGDMA, only becoming opaque at 0.7 M crosslinker. In 
contrast, PEGDMA-only hydrogels are opaque at lower crosslinker concentrations. At 
crosslinker concentrations higher than typically used in the literature, the PEGMDA 
hydrogels are nearly as transparent as PEG-PC gels. 
 
2.5 Discussion 
An ideal biomaterial for studying cell-material interactions should be easily tunable 
across physical properties relevant to the cell type and tissue of interest. Controllable 
mechanical properties in biomaterials are extremely valuable for understanding cell 
behavior in heart disease [52,53] and cancer [54], as cell phenotype [4,5,7,55] and stem 
cell differentiation [5,56,57] are sensitive to the modulus of the microenvironment. In vivo, 
a vascular SMC in a healthy arterial media experiences a microenvironment stiffness 
between 2 and 10 kPa [58,59], but in an atherosclerotic plaque, the substrate could have 
stiffness from tens [60,61] to hundreds of kPa [62]. During metastasis, a cancer cell must 
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migrate from a stiff, fibrotic tumor environment through more compliant interstitial tissues 
and blood vessel walls into the blood stream [63]. Matrix crosslinking and stiffness have 
profound effects on tumor malignancy [64] and cancer cell metastasis [63]. Other ideal 
features of hydrogels for mechanobiology include independently tunable stiffness and 
ligand density, hydrophilicity for reduction of non-specific protein adsorption, and optical 
clarity for modern quantitative microscopy techniques.  
Poly(ethylene glycol) (PEG) is a well characterized amphiphilic polymer widely 
used as a hydrogel crosslinker in biological applications due to its biocompatibility, 
mechanical tunability, and anti-fouling properties. However, while it is possible to lower 
the Young’s moduli by adding enzymatic degradation sites to the PEG monomers, 
PEGDMA hydrogels (MN ~750) cannot polymerize at concentrations ≤ 5 wt.%, limiting 
the range of moduli obtainable. Furthermore, PEGDMA hydrogels at most tissue-relevant 
moduli are opaque (Fig. 2.8C, D), reducing their attractiveness for high-resolution 
microscopy. 
In the present study, we describe and characterize a new PEG-PC hydrogel that 
improves upon all these properties.  PEG-PC hydrogels are composed of a PEGDMA 
crosslinker, co-polymerized with the PC zwitterion. PC-containing phospholipids are a 
major component of biological membranes, and PC-polymers exploit biocompatible 
moieties in synthetic constructs [65]. PC-containing hydrogels and PC-coated surfaces 
have been exploited for their anti-fouling properties and biocompatibility [65]  for use in 
applications such as contact lenses [66], cell encapsulation [67], and drug delivery [68]. 
There have been two prior reports of a similar polyMPC hydrogel crosslinked with ethylene 
glycol dimethacrylate and other crosslinkers [69,70]. However, these authors used a much 
60 
 
higher concentration of PC (2.5 M versus 0.6 M) and very short crosslinkers in comparison 
to PEG-PC, and the mechanical properties of the materials were not reported. 
Hydrogels which incorporate other zwitterion co-monomers have been studied, in 
particular sulfobetaines such as 1-(3-sulphopropyl)-2-vinyl-pyridinium-betaine [71,72] 
and N-(3-sulfopropyl)-N-(methacryloxyethyl)-N,N-dimethylammonium betaine [73], but 
not in cell culture contexts. Another approach to create hydrophilic hydrogels includes the 
incorporation of hyaluronic acid [14,16,20,29,74]. However, hyaluronic acid has some 
very undesirable properties, including polydispersity, very high cost, and the requirement 
of functionalization with organic chemistry. Plus, it is known to affect cell behavior 
through several different cell-surface receptors [75], which may be undesirable except in 
instances where the biological effects of hyaluronic acid are specifically being studied. On 
the other hand, PC has the advantages of being relatively inexpensive (especially compared 
to hyaluronic acid), biocompatible without affecting cell behavior, and simple integration 
into any methacrylate-functionalized hydrogel.  
We have successfully polymerized PEG-PC hydrogels using UV polymerization 
with as little as 7.4 mM (0.5 wt.%) PEGDMA crosslinker, and up to 0.3 M crosslinker 
without diminishing optical clarity (Fig. 2.8C, D). In contrast, PEGDMA hydrogels 
without PC comonomer cannot polymerize below approximately 70 mM crosslinker, and 
they are not optically transparent below 0.5 M. Polymerization at such a low crosslinker 
concentration imparts PEG-PC hydrogels with a wider range of mechanical properties: the 
Young’s moduli of PEG-PC ranges from 900 Pa with 7.4 mM crosslinker to nearly 10 MPa 
with 0.7 M crosslinker, which is more compliant at the low end of crosslinker concentration 
than is possible with PEGDMA hydrogels. This range of stiffnesses is greater than 
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obtainable with PEGDMA gels, and covers a biologically-relevant span that enables 
reproduction of nearly any biological tissue, e.g. liver (5-55 kPa) [76–78], spinal cord (89 
kPa), thyroid (9 kPa), breast tumor (4 kPa), carotid artery (90 kPa), and articular cartilage 
(950 kPa) [46]. While bone typically has a modulus from 10-20 GPa [79], PEG-PC 
hydrogels with moduli from 1 – 10 MPa may prove useful for studying osteoclasts and 
other bone-associated cell types. We have also demonstrated the polymerization of PEG-
PC with APS and TEMED free radical initiation, and find that differences in mechanical 
properties diminish with increasing crosslinker concentration (Fig. 2.4), most likely an 
effect of different crosslinker concentration-dependent reaction rates or efficiency. 
In addition to the exceptional mechanical range and optical properties, we have also 
demonstrated through BSA adsorption experiments that PEG-PC adsorbs less protein than 
a PEGDMA hydrogel of the same modulus (Fig. 2.8A), and the amount of adsorbed protein 
is inversely related to the PC content of the hydrogel (Fig. 2.8B). These results further 
confirm the non-fouling properties of PC, which enable a greater degree of control over 
protein presentation than PEGDMA hydrogels.  
From our characterization, we conclude that PEG-PC hydrogels outperform PEG 
hydrogels as a platform for mechanobiology, and this four order-of-magnitude range of 
Young’s moduli exceeds nearly every previously reported polymer or hydrogel reported 
for cell culture use, including the recent report of a more tunable version of PDMS [28]. 
We also discovered that the 135 mM crosslinker hydrogels had mesh sizes half that of a 
135 mM PEGDMA gel without PC, whereas the Young's modulus is nearly ten times 
higher [50], implying the inherent structural changes outlined in Figure 2.2. Two reports 
have demonstrated that hyaluronic acid hydrogels have a similarly wide tunable 
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mechanical range [14,16], however, they are significantly more expensive to prepare than 
PEG-PC gels, require a longer preparation time, and hyaluronic acid has inherent 
bioactivity that can confound interpretation of results.  
We propose two distinct phenomena at low and high concentrations of crosslinker 
to explain the remarkable mechanical properties of PEG-PC. At less than 70 mM (5 wt.%) 
crosslinker, PEGDMA does not form a gel.  However, integration of the PC polymer allows 
polymerization with as low as 7.4 mM PEGDMA (0.5 wt.%). This is likely due to the 
overall increase in polymer mass from the PC, which is then crosslinked by the bifunctional 
PEGs (Fig. 2.2A). Secondly, although PC is charge-neutral in solution due to an 
intramolecular salt bridge, the PC groups can form dipoles, and it is conceivable that 
entropic forces (increased water ordering around the PC zwitterions) extend the PEG 
chains, permitting hydrogel formation at low crosslinker concentration. We have 
polymerized PEG-PC hydrogels in both water and PBS, and found no differences in the 
resulting mechanical properties (data not shown), confirming that the mechanical 
properties of the gels are maintained in the presence of biologically relevant solvents and 
that salts do not affect polymer conformations. Regardless of the precise interactions 
responsible, the resulting hydrogels are far more compliant than with PEGDMA alone, due 
to the lower overall crosslinking density and increased swelling.   
At concentrations of PEGDMA above 135 mM, we observed a large change in the 
trends of mechanical properties as a function of crosslinker concentration. We 
hypothesized these effects result from a fundamental change in the structure of the 
hydrogel, specifically by PEGDMA becoming the dominant hydrogel component, as 
illustrated in the two extremes of very low and very high PEGDMA concentration in Figure 
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2.2. In this regime, where there is more PEGDMA mass per volume than PC, the 
dependency of both mesh size and Young’s modulus on crosslinker concentration is much 
weaker than in the low PEGDMA regime.  
The proposed ability to form two very different polymer structures with the same 
two components may also help explain the impressive mechanical range that PEG-PC 
hydrogels achieve. The structural differences responsible for the regime transition just 
described may be why we consistently observed linear stress-strain curves in the PC > 
PEGDMA regime and small portions of nonlinearity (up to 1 or 2% strain) in the PEGDMA 
> PC regime (Fig. 2.6). This has potential cellular significance due to the recent report that 
cell phenotype is sensitive to whether a material is linearly elastic or not [51]. However, 
we could not directly compare results, as we observed non-linearity at low strain in high 
modulus gels, whereas these authors observed non-linearity at high strain in low modulus 
gels, implying inherently different networks. Our results on the effect of varying [PC] with 
constant total polymer fraction, and those comparing swelling properties of PEGDMA gels 
copolymerized with varying amounts of PC and PEGMA, further confirm the 
hydrophilicity of PC and its impact on modulus and water uptake. These characteristics 
lend further support to the hypothesis that entropic forces from PC may be extending 
PEGDMA polymer chains and thereby increasing mesh size and decreasing modulus, an 
effect which is presumably diminished in the PEGDMA > PC regime.  
 
2.6 Conclusion 
We have developed a new class of hydrogels by combining the tunability and 
versatility of PEG hydrogels with biomimetic comonomer, PC. These hydrogels have an 
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extremely wide, 4 order of magnitude range of mechanical properties, with the additional 
advantages of being inexpensive, simple to synthesize, and optically clear. PEG-PC gels 
can be used to study mechanobiology across many different cell types, and we encourage 
others to adapt this system to study cellular responses to ECM modulus. 
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CHAPTER 3 
CANCER CELL MECHANOTRANSDUCTION VARIES WITH CELL TYPE 
 
3.1 Abstract 
In the following chapter, I will demonstrate the utility of PEG-PC hydrogels for use 
in in vitro disease research. This work is a proof-of-concept study to show that PEG-PC 
hydrogels can be surface-functionalized with full-length extracellular matrix proteins and 
this promotes cell attachment and adhesion, and to investigate the impact of substrate 
modulus on proliferation and focal adhesion properties of multiple cancer cell lines 
(HEP3B, MB-MDA-231, SkBr3). This work also extensively utilizes PEG-PC hydrogels 
synthesized in a 96-well microplate format for high-throughput screening and other in vitro 
assays. The findings herein are the first reported study on the impact that substrate modulus 
has on the proliferation of these cancer cell lines, which has relevance to understanding the 
roles of tumor stiffening and fibrosis in vivo. 
  
3.2 Introduction 
 In modern medicine, there is a somewhat narrow-minded focus on the importance 
of genetics in understanding development and disease, and for treating disease. While the 
revolutions in technology that enabled genetic research are technically impressive and 
critically important, the hyping of the importance of genetics has led many researchers 
towards the belief that only genetics matter. This is a troubling trend, but it is one which is 
slowly being pushed back against by work in the field of mechanobiology. It is troubling 
because the medical community has long known that mechanics has an important role in 
development and disease [1], and if biomedical researchers continue to ignore or downplay 
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the importance of the physical microenvironment we may miss opportunities to develop 
life-saving cures and treatments. 
 The revelation that mechanics is vitally important in human physiology may be 
traced back to Wolff’s Law from the late 1800’s, which essentially states that bone 
responds to the mechanical load placed upon it through an adaptive response that increases 
the density of the internal trabeculae [2]. Now, we know that mechanotransduction – the 
ability of cells to sense and respond to changes in their mechanical environment – is a 
factor in a very large list of diseases, including many of the most costly diseases such as 
atherosclerosis, cancer (and metastasis), hypertension, pulmonary fibrosis, irritable bowel 
syndrome, osteoporosis, and sexual dysfunction (plus many more [1]). Diseases may be 
caused, or modulated by, defects in the conversion of mechanical signals to chemical 
signals (e.g. several muscular dystrophies [3], atrial fibrillation [4], osteoporosis [5]), 
changes in extracellular matrix composition (ECM) or structure (e.g. some muscular 
dystrophies [6], Marfan’s syndrome [7], cancer [8,9]), or alterations to the contractile 
apparatus within cells (e.g. some types of deafness and blindness, cardiomyopathy [10], 
sexual dysfunction [11]). While many of the mechanically-related causes or consequences 
of disease may have a genetic basis, we may be able to discover and develop treatments, 
or even cures, for many diseases if we can address the underlying mechanical dysfunction, 
without the need for gene therapy. 
 A lot of work in the field of mechanobiology has focused on the use of 2D 
polymeric biomaterials to modulate static mechanics. This approach is based on the 
observation that integrin-ECM interactions, and the focal adhesion signaling complexes 
they engender, are the primary means of transducing mechanical signals from the exterior 
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of the cell into internal signaling. Due to the existence of many different types of ECM 
proteins and integrin heterodimers, exactly how, and what signals are transduced in any 
given context is highly complex and depends on cell type (and species), the tertiary 
structure of the ECM proteins, and potential interactions between soluble factors and 
integrins and/or ECM proteins. Thus, due in part to the ease with which many cell types 
are cultured on 2D surfaces, many groups have developed and used tunable polymeric 
biomaterials to modulate substrate stiffness, especially hydrogels. These materials enable 
researchers to examine how changes in stiffness may modulate disease states in different 
microenvironment contexts (e.g. ECM proteins, soluble factors).  
Here, we demonstrate the use of our novel PEG-PC hydrogel in a mechanobiology 
study to examine the influence of substrate stiffness on the proliferation and focal adhesion 
properties of multiple cancer cell lines. We find that the dependence of proliferation on 
stiffness varies across cell types, including one cell line which actually proliferates less on 
stiff substrates. These cell-specific effects are likely due to differences in expression of 
integrins, focal adhesion-associated signaling proteins, and/or contractile apparatus 
proteins.  
 
3.3 Materials & methods 
3.3.1 Cell culture 
All cells and culture media reagents were purchased from Life Technologies, 
Carlsbad, CA, unless otherwise noted. Human aortic smooth muscle cells (HASMCs) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% 
penicillin-streptomycin (P/S) and smooth muscle growth supplement (SMGS).  Human 
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hepatocellular carcinoma cells (HEP3Bs, American Type Culture Collection, Manassas, 
VA), were cultured in modified Eagle’s medium (MEM) supplemented with 1% P/S and 
10% FBS. Human SkBr3 and MDA-MB-231 (231) breast carcinoma cell lines were 
generous gifts from Shannon Hughes at the Massachusetts Institute of Technology and 
Sallie Schneider at the Pioneer Valley Life Sciences Institute, respectively. Both SkBr3 
and 231 cell lines were cultured in DMEM supplemented with 1% P/S and 10% FBS. 
 
3.3.2 Synthesis of PEG-PC hydrogels 
PEG-PC polymer hydrogel precursor solutions were prepared by mixing PEGDMA 
(average Mn 750, Sigma-Aldrich, St. Louis, MO), to final concentrations of 29, 47, 84 and 
122 mM (2.2 – 9.2 wt.%, see Figure 2.2E), and 0.6 M (17 wt.%) 2-methacryloyloxyethyl 
phosphorylcholine (MPC; Sigma-Aldrich) in phosphate buffered saline (PBS). Solutions 
were degassed for 30 seconds with nitrogen, and sterilized with a 0.2 µm syringe filter 
(Thermo Fisher Scientific, Waltham, MA). Hydrogels were polymerized by adding 0.05 
wt.% ammonium persulfate (APS, from a 20 wt.% stock in water; Bio-Rad Laboratories, 
Hercules, CA) and 0.125 vol.% tetramethylethylenediamine (TEMED, Bio-Rad 
Laboratories) and cured in an O2-free atmosphere.  
To make thin PEG-PC hydrogels with even heights suitable for microscopy, 75 µL 
aliquots of PEG-PC solution was cured between chemically modified 18 mm glass 
coverslips with APS and TEMED polymerization, on the bench at room temperature. 
Methacrylate silanized coverslips served as the base, and covalently attached to the 
hydrogel during polymerization, whereas hydrophobic coverslips could be easily removed 
from the final, hydrophilic hydrogels.  To create the methacrylate coverslips, slips were 
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treated with O2 plasma for 10 minutes, reacted in 200 mL of 95% ethanol with 2 vol.% 3-
(trimethoxysilyl) propyl methacrylate (adjusted to pH 5.0 with glacial acetic acid; Thermo 
Fisher Scientific) for 2 minutes with shaking, washed three times in 200 proof ethanol, and 
finally dried at 120°C for 15 minutes[12]. Hydrophobic coverslips were made with 
coverslips submerged in Sigmacote (Sigma-Aldrich), shaken for 20 minutes, washed 3 
times with 200 proof ethanol, and dried under vacuum.  Following polymerization, the 
Sigmacote cover slips were removed from the gel surface with fine forceps, and the gels 
were allowed to swell in sterile PBS for 24 hours. Prepared coverslips were stored in foil 
in a dessicator at room temperature. 
To synthesize PEG-PC hydrogels for high throughput applications, 96-well 
microplates with glass bottoms (no. 1.5 coverslip glass; In Vitro Scientific, Sunnyvale, CA) 
were treated with O2 plasma for 10 minutes, reacted with 100 µL/well of 2 vol.% 3-
(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich) in 95% ethanol (to pH 5.0 with 
glacial acetic acid; Thermo Fisher Scientific) for 2 minutes, with shaking, then rinsed 3x 
with 200 proof ethanol, and dried at 40°C for 30 minutes. To polymerize hydrogels in 
wells, pre-polymer solutions were prepared with APS and TEMED polymerization as 
described above, and added to the 96-well plate at 40 µL/well. Oxygen was purged by 
placing plates in a vacuum oven at room temperature and flushing pure N2 gas through the 
chamber for 5 minutes, then sealing the chamber for 10 minutes to complete the reaction. 
Finally, hydrogels were swelled overnight with 100 µL/well PBS.      
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3.3.3 Protein functionalization 
To facilitate cell adhesion to the gels, proteins were covalently attached to the 
hydrogel surfaces. Hydrated gels on coverslips were transferred to 12-well tissue culture 
dishes and treated twice with sulfo-SANPAH (0.3 mg/mL in pH 8.5 HEPES buffer; 
ProteoChem, Denver, CO) under UV light for 15 minutes. The gels were washed by twice 
pipetting sterile PBS directly over the surface and shaking for 10 seconds, followed 
immediately by incubation with protein cocktails. For gels in 96-well plates, 100 µL of 0.6 
mg/mL sulfo-SANPAH was added to each well and the plates exposed to UV light for 20 
minutes and then briefly washed three times with HEPES buffer. To demonstrate 
versatility, we also showed that acrylate-poly(ethylene glycol)-succinimidyl valerate 
(PEG-SVA; Laysan Bio, Arab, AL) can crosslink proteins by adding it to the PEG-PC pre-
hydrogel solution at 0.11 wt.%.  This method incorporates an amine reactive group into the 
bulk of the hydrogel instead of isolating the reaction at the surface.   
After reacting the gel surfaces with the heterobifunctional crosslinker, hydrogels 
presented a highly amine-reactive functional group for covalent linkage to a variety of 
integrin-binding proteins. We made two different mixtures of integrin-binding proteins 
(protein “cocktails”), which consisted of either integrin-binding ECM proteins that are 
found in typical basement membranes (70% collagen III, 15% collagen IV and 15% 
laminin at 10 µg/cm2), or in inflammation and wound healing (50% collagen I and 50% 
fibronectin at 10 µg/cm2). The proteins used were type I collagen (rat tail) and laminin 
(mouse) (both from Life Technologies), recombinant human collagen III (FibroGen, San 
Francisco, CA), recombinant human collagen IV (Neuromics, Edina, MN), and human 
plasma fibronectin (EMD Millipore, Billerica, MA). Protein cocktails were made in sterile 
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PBS and adjusted to pH 3 to prevent collagen gelation. Post-protein reaction, hydrogels 
were washed 3x over an hour in sterile PBS with shaking, and then UV sterilized for 60 
minutes before cell seeding. 
 
3.3.4 Quantification of protein coupling 
We quantified protein coupling to the hydrogels with an indirect ELISA[13]. 
Hydrogels were polymerized on coverslips, swelled in PBS overnight, and coupled with 
varying concentrations of recombinant human collagen III (Fibrogen, San Francisco, CA) 
with sulfo-SANPAH, as described above. The gels were washed 5x with PBS, incubated 
with primary antibody to collagen III (clone 1E7; Santa Cruz Biotechnology, Dallas, TX) 
in PBS, at 37°C for 90 minutes, washed again 5x with PBS, and incubated with secondary 
antibody conjugated to horseradish peroxidase (HRP; Abcam, Cambridge, UK) at 37°C for 
90 minutes. After washing 5x with PBS, the gels were incubated with 0.1 mg/mL 3,3’,5,5’-
tetramethylbenzidine (TMB; Sigma-Aldrich) and 0.06% hydrogen peroxide (Thermo 
Fisher Scientific) in 0.1 M sodium acetate (pH 5.5; Sigma-Aldrich) for 40 minutes at room 
temperature with shaking. Immediately, an equal volume of 1 M sulfuric acid (Sigma) was 
added to each well, and the absorbance at 450 nm was measured with a BioTek ELx800 
absorbance microplate reader (BioTek, Winooski, VT). 
 
3.3.5 Focal adhesion quantification and imaging 
All cell lines were seeded in serum-free DMEM (with the exception of HEP3Bs, 
which were seeded in MEM) on 18, 26, 165 and 400 kPa PEG-PC hydrogels coupled with 
10 µg/cm2 collagen I. After 48 hours, cells were rinsed 2x with warm PBS, fixed in fresh 
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4% formaldehyde, and blocked with AbDil (2% BSA in Tris-buffered saline with 0.1% 
Triton X-100, TBS-T). Vinculin was immunofluorescently labeled with a monoclonal 
mouse anti-vinculin antibody (Sigma-Aldrich) and an anti-mouse FITC secondary 
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA).  F-actin was 
fluorescently labeled with Alexa Fluor 555-conjugated phalloidin (Life Technologies), and 
cell nuclei were labeled with DAPI (MP Biomedicals, Santa Ana, CA). Antibody 
incubations were performed for 1 hour in AbDil, in the dark, and cells were thoroughly 
washed between labeling steps with TBS-T.  Each sample was equilibrated with ProLong 
Gold antifade reagent (Life Technologies) for 5 minutes before imaging. Images were 
taken with a 63x oil immersion objective, on a Zeiss Axio Observer Z1 microscope (Carl 
Zeiss, Oberkochen, Germany), and ImageJ [14] was used to adjust the brightness and 
contrast for clarity in figures. With unmodified images, ImageJ's built-in measurement 
functions were used to quantify focal adhesion area and circularity. A minimum of 42 focal 
adhesions were manually traced from a minimum of 8 cells per condition.  
 
3.3.6 Cell proliferation 
In 96-well glass-bottomed plates, PEG-PC hydrogels with Young’s moduli of 18, 
26, 165 and 400 kPa were polymerized with APS and TEMED. Sulfo-SANPAH was used 
to attach collagen I at 10 µg/cm2, as described above. 231s and SkBr3s were seeded at 
6,000 cells/well in serum-free DMEM with 1% P/S; HEP3B cells were seeded at 6,000 
cells/well in MEM media with 10% FBS and 1% P/S. In all cases, the media was exchanged 
for serum-containing media (10% FBS) 24 hours after seeding and was replenished every 
two days. Five days after seeding, the MTS-based assay CellTiter96 AQueous (Promega, 
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Madison, WI) was added to each well at 20 µL/well to indirectly measure cell proliferation 
via mitochondrial redox activity. After 4 hours of incubation, the absorbance was read at 
490 nm with a BioTek ELx800 (BioTeK) absorbance microplate reader. In order to 
demonstrate how cell number changes as a function of hydrogel modulus, the data is 
presented as a fold-increase in absorbance compared to the softest (18 kPa) hydrogel tested. 
 
3.3.7 Statistical analysis 
Statistical analysis was performed using Prism v5.04 (GraphPad Software, La Jolla, 
CA).  Data are reported as mean ± standard deviation, unless otherwise noted. Statistical 
significance of the difference between pairs of means was evaluated by computing P-values 
with unpaired Student's t-tests (with Welch's correction as necessary). When one-way 
ANOVAs were performed, the statistical significance of pairwise differences was 
determined with the Tukey post-test. P ≤ 0.05 is denoted with *, ≤ 0.01 with **, ≤ 0.001 
with *** and ≤ 0.0001 with ****; P > 0.05 is considered not significant ('ns'). 
 
3.4 Results 
3.4.1 Protein surface density can be controlled with sulfo-SANPAH 
 To demonstrate that sulfo-SANPAH coupling of proteins to PEG-PC is robust and 
controllable, we coupled PEG-PC hydrogels (84 mM PEGDMA) with 5, 10 and 20 µg/cm2 
(theoretical) of collagen III and indirectly measured the relative concentrations with an 
ELISA assay (Fig. 3.1). We found that the ELISA signal is linearly proportional to the 
theoretical concentration of collagen III protein (R2 = 0.9622). This result confirms the 
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coupling of proteins to PEG-PC with sulfo-SANPAH, and that this process can be precisely 
controlled to achieve different surface concentrations of proteins. 
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Figure 3.1: Control of PEG-PC protein surface concentration with sulfo-SANPAH 
With an ELISA assay, we demonstrate that the surface concentration of proteins coupled 
to PEG-PC with sulfo-SANPAH is controllable, and linearly proportional to protein 
concentrations in solution. 
 
3.4.2 Cells adhere and spread to protein-coupled PEG-PC surfaces 
We covalently attached integrin-binding ECM proteins to the surface of PEG-PC 
hydrogels with two methods: sulfo-SANPAH and PEG-SVA. Both methods enabled cell 
attachment and spreading on the PEG-PC surfaces (Fig. 3.2A) with multiple cell types (Fig. 
3.2B), and different protein mixtures (Fig. 3.2C).  As shown in Figure 3.2A, no cell 
attachment or spreading occurs on PEG-PC surfaces without sulfo-SANPAH or PEG-SVA 
modification, demonstrating again that PEG-PC hydrogels are non-fouling, and useful for 
studies in which parsing the roles of integrin-binding vs. mechanical properties is desired.  
With coupling, however, extensive cell spreading was observed consistently for all cell 
types we tested (examples shown are left: smooth muscle, right: liver carcinoma). 
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Figure 3.2: Modulus and integrin-binding on PEG-PC gels modulates cell morphology 
(a) (Left) HASMCs on PEG-PC (84 mM PEGDMA) treated with (top) or without (bottom) 
sulfo-SANPAH and collagen I at 10 µg/cm2, scale bar is 100 µm. (Right) HEP3B cells on 
PEG-PC (22 mM PEGDMA) with (top) or without (bottom) PEG-succinimidyl valerate 
(PEG-SVA) and 65% collagen III, 23% collagen I and 2% fibronectin at 5 µg/cm2, scale 
bar is 200 µm.  (b) i - ii: HASMCs on PEG-PC (compliant = 15 and stiff = 84 mM 
PEGDMA, 3 and 170 kPa, respectively, except for SkBr3 for which stiff = 0.15 M 
PEGDMA and 400 kPa) with collagen I. Vinculin = green, F-actin = red, and DNA = blue. 
iii – iv: HEP3Bs. v - vi: MDA-MB-231s, and vii - viii: SkBr3s. Scale bar is 20 µm. (c) 
HASMCs on basement membrane-like ECM (70% collagen III, 15% each collagen IV and 
laminin at 10 µg/cm2 total) and on inflammatory ECM (50% each fibronectin and collagen 
I at 10 µg/cm2 total). Scale bar is 20 µm. Figure adapted with permission from [15], 
Copyright © 2013 American Chemical Society. 
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3.4.3 Substrate modulus controls focal adhesion maturity  
Going further, we demonstrated that cells sense differences in the stiffness of PEG-
PC hydrogels coupled with 10 µg/cm2 collagen I by performing experiments with three 
human cell types: liver carcinoma (HEP3B) and two breast cancer cell lines (SkBr3 and 
MDA-MB-231) (Fig. 3.2B). After 48 hours of culture, cells were fixed and stained for actin 
(red), DNA (blue) and vinculin (green). Vinculin staining was used to identify focal 
adhesions [16], which were counted and analyzed with ImageJ (Fig. 3.3A). We manually 
traced focal adhesions at 4 stiffnesses to quantify the number of focal adhesions visible per 
cell (Fig. 3.3B), the average focal adhesion area (Fig. 3.3C) and elongation (Fig. 3.3D). 
Focal adhesion circularity was quantified with ImageJ as a measure of adhesion maturity, 
with elongation (circularity-1) being associated with increased adhesion stability (Fig. 
3.3D) [17].   
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Figure 3.3: PEG-PC modulus control of focal adhesions is cell-specific 
(a) Example of image thresholding and focal adhesion tracing performed in ImageJ of an 
SkBr3 cell with labeled vinculin. (b) Average number of focal adhesions (FA) counted per 
cell as a function of PEG-PC modulus with 10 µg/cm2 collagen I. HEP3B cells had 
significantly fewer focal adhesions on the 165 and 400 kPa PEG-PC gels than on the 18 
kPa gels, as measured with one-way ANOVA and the Tukey post-test for significance. (c) 
Average focal adhesion area on 18 – 400 kPa PEG-PC with 10 µg/cm2 collagen I. (d) 
Average focal adhesion elongation (departure from circularity) on 18 – 400 kPa PEG-PC 
with 10 µg/cm2 collagen I. SkBr3 focal adhesion elongation decreased by 37% from 18 to 
400 kPa. Figure adapted with permission from [15], Copyright © 2013 American Chemical 
Society. 
 
We observed that focal adhesion area decreased with Young’s modulus in SkBr3 
and 231 cells (Fig. 3.3C; areas on the stiffest PEG-PC were reduced approximately 37 and 
45% from the softer PEG-PC hydrogels, p < 0.05 and p < 0.01, respectively), and SkBr3 
elongation also decreased with increasing stiffness. Interestingly, HEP3B focal adhesion 
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area is biphasic (Fig. 3.3C; area on 26 kPa PEG-PC is 65% larger than on 18 and 165 kPa, 
p < 0.01), and they were also the only cell line to have a significantly different number of 
focal adhesions per cell. Both HEP3Bs and MDA-MB-231s had very few cells with actin 
stress fibers, but many cells had prevalent, actin-rich filopodia (Fig. 3.2B iii-iv, v-vi).  
These results demonstrate the ability of PEG-PC hydrogel mechanical properties to 
modulate cytoskeletal organization, and revealed that mechanosensitivity is cell line-
specific.   
 
3.4.4 The effect of substrate modulus on proliferation is cell type-specific 
We investigated the role of substrate stiffness on the proliferation of three types of 
cancer cells. HEP3Bs, SkBr3s and 231s were each seeded on PEG-PC gels across a range 
of modulus with 10 µg/cm2 collagen I. We found that 231 proliferation increases by 
approximately 25-35% (over the reading on 18 kPa hydrogels), for hydrogels between 18 
and 26 kPa, before saturating (Fig. 3.4A). HEP3Bs were most sensitive to substrate 
modulus, with average proliferation increasing about 60% from 18 kPa to 26 kPa, and then 
another 60% from 26 kPa to 165 kPa (Fig. 3.4C). Finally, SkBr3s proliferation decreased 
by 25% between 26 kPa and 165 kPa, and another 25% between 165 kPa and 400 kPa (Fig. 
3.4B).  
We connect these proliferation results with our analysis of focal adhesions using 
simple statistical methods. For instance, HEP3B cells proliferated substantially more on 
stiff substrates, but they had fewer focal adhesions on these substrates; in contrast, SkBr3 
cells proliferate less on the stiffer substrates, with smaller focal adhesions. Finally, 231 cell 
proliferation increased marginally with stiffness, and their focal adhesions were also 
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minimally affected by substrate modulus. These three contrasting trends imply differing 
degrees of interconnectedness of adhesion, contractile and proliferation signaling pathways 
in these cell types. Although the mechanisms of this behavior are outside the scope of this 
particular study, we quantified the correlations, if any, between focal adhesion number, 
area, elongation, and cell proliferation for each cell type. Using the Spearman correlation 
coefficient we find that SkBr3 focal adhesion area and elongation are strongly correlated 
with proliferation (R = 1 and 0.8, respectively), and HEP3B focal adhesion number is 
inversely correlated with proliferation (R = -0.8). 
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Figure 3.4: PEG-PC modulus affects cellular proliferation 
HEP3B (●), MDA-MB-231 (■), and SkBr3 (▲) cells were grown on PEG-PC from 18 to 
400 kPa for 5 days and their proliferation quantified with CellTiter96. Results are presented 
as arbitrary absorbance units normalized to the 18 kPa condition for each cell type (reported 
as “1”). 231s and SkBr3s display minor dependence of proliferation on substrate modulus, 
but with opposing trends. However, HEP3B proliferation is strongly and positively 
affected by substrate modulus. Error bars are standard error, with N=4, for 231s, N=3 for 
SkBr3s and N=2 for HEP3Bs. Figure adapted with permission from [15], Copyright © 
2013 American Chemical Society. 
 
3.5 Discussion 
In the mechanobiology field, researchers are interested in the availability of 
biocompatible materials with tunable mechanical properties that can probe how cells sense 
mechanical forces, and the role that mechanical forces may have in disease and 
development. Moreover, materials for these applications must be capable of being 
functionalized with adhesive ligands, be they full-length ECM proteins or adhesive peptide 
sequences. In this work, we have investigated the suitability of PEG-PC as a hydrogel for 
these applications. In addition to the exceptional mechanical properties described in 
Chapter 2, we have shown here that full-length proteins can be coupled to PEG-PC surfaces 
with sulfo-SANPAH and UV light, or alternatively by the addition of PEG-SVA to the 
hydrogel bulk polymer (Fig. 3.2A). The attachment of ECM proteins supports cell adhesion 
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and spreading on PEG-PC (Fig. 3.2), and the amount of protein coupled with sulfo-
SANPAH can be controlled by adjusting the protein concentration in solution during the 
reaction (Fig. 3.1).  
As proof of concept in mechanobiology, we cultured several cell lines (HASMCs, 
HEP3Bs, and several breast cancer cell lines: SkBr3 and 231 shown here, BT-549 and 
others not shown) on PEG-PC gels from 3 to 400 kPa Young's moduli functionalized with 
collagen I, and quantified the effect of substrate stiffness on cell morphology and focal 
adhesion number, size and elongation. The relationship between focal adhesion properties 
and substrate modulus was cell type-dependent (Fig. 3.3B-D), as was the relation between 
focal adhesion properties and proliferation. Mechanobiology reports with these cell lines 
is limited, but one group reported a decrease in the relative adhesivity of 231s with 
increasing stiffness [18]. This report supports our findings that focal adhesion area 
decreases with stiffness, but a direct comparison cannot be drawn due to experimental 
differences.  
Comparing our focal adhesion quantification with proliferation has revealed cell 
type-specific differences in mechanotransduction. These different trends highlight how cell 
type-specific differences in mechanotransduction machinery reported elsewhere (integrins, 
adhesion proteins, actin, myosin and many more [19,20]) can result in very different 
mechanosensing properties and subsequent changes in pathway signaling. To our 
knowledge, this is the first report on the effects of 2D substrate stiffness on proliferation in 
these cell types. Other, previously available mechanotransduction data on these cell lines 
is limited, and our results may guide future research. We propose that PEG-PC hydrogels 
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are ideal for studies of mechanobiology or mechanotransduction, development, and 
stiffness-associated disease states such as cancer and atherosclerosis. 
 
3.6 Conclusions 
We have shown that PEG-PC can be functionalized, with control, to support cell 
adhesion and spreading in 2D, and demonstrated the mechanosensing of 3 cancer cell lines 
over a range of ~380 kPa Young’s modulus. All 3 cell lines had varying responses to 
changes in stiffness, as reflected in their proliferation rates and focal adhesion shape, size 
and number. These results, plus PEG-PC’s exceptional mechanical, optical and fouling 
properties, prove it to be an excellent choice for future studies in these areas. 
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CHAPTER 4 
EXTRACELLULAR MATRIX COMPOSITION IS THE MAJOR DRIVER OF 
SMC PHENOTYPE AND BEHAVIORS 
 
4.1 Abstract 
The aim of the work described in this chapter is to gain a deeper understanding of 
how the changing microenvironment affects smooth muscle cell (SMC) phenotype and 
behaviors in atherosclerosis. We have designed a complex in vitro model to recapitulate 
characteristic changes in the composition of the surrounding extracellular matrix (ECM), 
soluble factors, and vessel wall stiffness that SMCs undergo in this disease. We found that 
ECM composition is the primary regulator of cell behaviors, and modulates the effects of 
soluble factors, whereas stiffness had an unexpectedly modest role. Surprisingly, in direct 
conflict with previous studies, we did not find that proliferation and migration are inversely 
related to SMC marker expression. Cell signaling studies revealed that marker expression 
is mediated chiefly via focal adhesion kinase (FAK) signaling, with additional evidence of 
ECM-specific differences in their regulation downstream of FAK. Finally, our findings 
suggests that longstanding disagreement regarding the distinction between proliferative 
and migratory phenotypes in SMCs is well-explained by the changing ECM composition, 
and we propose hypothetical, integrin-driven models to explain this switchover. From these 
results we conclude the importance of increasing the complexity of in vitro models to 
carefully match critical features of in vivo microenvironments, which will induce 
physiological behaviors and aid in identification of novel drug targets and treatments. 
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4.2 Introduction 
Heart disease is the leading cause of mortality worldwide, accounting for over 30% 
of all deaths [1]. Smooth muscle cells (SMCs) play an important role in atherosclerosis, 
the pathological condition that leads to most cerebrovascular- and cardiovascular disease-
related deaths. These normally quiescent, immobilized cells are induced to migrate from 
the arterial media to the developing plaque where they may rapidly proliferate and 
contribute to plaque volume and instability. During this invasion process, SMCs are 
subjected to significant changes in their local microenvironment, including the 
composition of the surrounding extracellular matrix (ECM), the availability of soluble 
factors, and the stiffness of the vessel wall.  
Due to their role in arterial mechanics, SMCs – along with fibroblasts, a closely 
related cell type – have been the subject of many studies in the fields of 
mechanotransduction and biomechanics. Of major interest to these fields are the effects of 
substrate compliance and ECM proteins on aberrant SMC behavior in atherosclerosis, 
particularly proliferation and migration. These characteristics are typically tested with 
biocompatible hydrogels [2–5] having tunable mechanical properties and the ability to be 
coupled with adhesive ECM proteins. With these in vitro model systems, some common 
trends have emerged. Typically, proliferation is positively correlated with substrate 
compliance in SMCs [6,7] and other cells [8], but reports vary based on the material and 
cell type [9,10]. ECM proteins and other adhesive ligands are also capable of regulating 
proliferation and migration of SMCs [2,11] and other cell types, and of modulating the 
effects of soluble growth factors (GFs) and cytokines [4,12,13].  
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However, many of these in vitro studies do not reproduce, or in some cases, conflict 
with conclusions derived from in vivo studies. For example, SMCs reside on a spectrum of 
phenotypes, yet only two phenotypes are typically described: in a healthy, intact arterial 
media, SMCs are differentiated and ‘contractile,’ whereas proliferative SMCs in an 
atherosclerotic lesion are in the dedifferentiated, ‘synthetic’ phenotype. Further, SMC 
proliferation and marker expression (and therefore differentiation) are typically regarded 
to be inversely related [14–17], but conflicting reports [18–21]  raise serious questions 
regarding the true diversity of SMC phenotypes and the interrelation between the 
extracellular environment, phenotype, and pathological behaviors. Despite the 
comparatively simplistic designs of the in vitro models used, these prior studies have 
nevertheless revealed substantial and vital information concerning the effects of local 
stimuli on cellular phenotype and behaviors that are the foundation of the work described 
here.  
Given that the arterial microenvironment is much more complex and heterogeneous 
than a typical in vitro model, we hypothesize that some – and possibly many – conflicts 
between in vitro and in vivo findings are due to the loss of signaling complexity that occurs 
when a complex in vivo microenvironment is reduced and simplified for in vitro studies. 
We believe that conflicts in the literature such as these, as well as the high failure rate of 
drug candidates in pre-clinical and phase I clinical trials, can potentially be explained by 
significant differences between human biology, in vitro models, and animal models.  
In response, we investigated the diversity of SMC phenotypes and behaviors with 
a polymeric biomaterial system designed to recapitulate not only multiple major features 
(physical, chemical, and mechanical) of the in vivo microenvironment, but also the changes 
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in these features that SMCs experience during invasion of a plaque. We used poly(ethylene 
glycol) dimethacrylate-phosphorylcholine (PEG-PC) hydrogels [9,22],  described in 
Chapter 2, as a tunable biomaterial substrate, and coupled them with mixtures of integrin-
binding ECM proteins representative of the changing arterial microenvironment. We 
forced SMCs into the contractile phenotype with a series of media changes, and then 
quantified their plasticity toward the synthetic phenotype and pathological cell behaviors 
as modulated by substrate stiffness, ECM/integrin binding, and soluble factors.  
Foremost, our results show that ECM/integrin binding is the most significant factor 
in regulating SMC behaviors and modulating the effects of soluble factors. Our data also 
strongly suggests that literature conflicts regarding the distinction between migratory and 
proliferative phenotypes may be best explained by the changes in the surrounding ECM 
composition, which is natively captured in in vivo studies, but not in simpler in vitro 
models. Strikingly, many of our results do not agree with some widely-accepted notions 
about SMC phenotype in vitro, most notably our finding that SMC proliferation is not 
inversely correlated with contractile marker expression in our system, nor is marker 
expression related to SMC morphology. We also found that marker expression is primarily 
regulated by focal adhesion kinase (FAK) signaling through phosphatidylinositol 3-kinase 
(PI3K) and Akt. Finally, we present a detailed, hypothetical model that fits very well with 
observations from this and many other reports, and describes a plausible mechanism by 
which integrin binding controls the switch from a migratory to proliferative phenotype. 
This study represents an early step towards closer replication of the in vivo 
microenvironment, and we hope our work will inspire others to carefully consider the 
effects of numerous relevant stimuli on SMC behavior, with any tunable platform.  
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4.3 Materials & methods 
4.3.1 Cell culture 
All cells and culture media reagents were purchased from Life Technologies, 
Carlsbad, CA, unless otherwise noted. Human aortic smooth muscle cells (HASMCs) from 
passages 2 through 8 were routinely cultured in Medium 231 supplemented with 1% 
penicillin-streptomycin (P/S) and smooth muscle growth supplement (SMGS; contains 
4.9% FBS, 2 ng/mL human basic fibroblast growth factor, 0.5 ng/mL human epidermal 
growth factor, 5 ng/mL heparin, 2 µg/mL recombinant human insulin-like growth factor-I, 
and 0.2 µg/mL bovine serum albumin). 1% P/S was used in all media types. Experiments 
were performed by trypsinizing confluent HASMCs on tissue culture plastic, resuspending 
in Dulbecco’s modified Eagle’s medium (DMEM) and 10% fetal bovine serum (FBS) and 
seeding on ECM-coated PEG-PC samples. Cells were synched into the contractile 
phenotype 24 hours post-seeding by briefly washing with serum-free DMEM and then 
treating with serum-free DMEM for 48 hours, then stimulating with 2.5 ng/mL 
recombinant human TGFβ1 (R&D Systems, Minneapolis, MN) in serum-free DMEM for 
an additional 48 hours. Finally, media was changed to DMEM supplemented with either 
SMGS (‘growth medium’), or smooth muscle differentiation supplement (SMDS; contains 
30 µg/mL heparin and 1% FBS; ‘differentiation medium’) for 48-96 hours, depending on 
the experiment.  
 
4.3.2 PEG-PC hydrogel polymerization and contact mechanics measurements 
As a base for 2D PEG-PC hydrogels, 15 mm no. 2 glass coverslips (Thermo Fisher 
Scientific, Waltham, MA) were treated with a UV Ozone ProCleaner for 10 minutes 
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(BioForce Nanosciences, Las Vegas, NV), and reacted with 50 mL of 95% ethanol 
(adjusted to pH 5.0 with glacial acetic acid; Thermo Fisher Scientific) with 2 vol.% 3-
(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich, St. Louis, MO) for 2 minutes with 
shaking, washed three times in 200 proof ethanol, and dried at 120C for 20 minutes [23]. 
Prepared coverslips were wrapped in aluminum foil and stored in a desiccator at room 
temperature.  
PEG-PC polymer hydrogel precursor solutions were prepared by mixing PEGDMA 
(average Mn 750, Sigma-Aldrich), between final concentrations of 14.7 mM and 0.135 M 
(1.1 - 10.1 wt.%), and 0.6 M (17 wt.%) 2-methacryloyloxyethyl phosphorylcholine (Sigma-
Aldrich; Fig. 4.1) in phosphate buffered saline (PBS).  Solutions were sterilized with a 0.2 
µm syringe filter (Thermo Fisher Scientific) and degassed for 30 seconds with grade 5.0 
nitrogen gas. Free-radical polymerization was induced with the addition of 0.125 vol.% 
tetramethylethylenediamine (TEMED, Bio-Rad Laboratories, Hercules, CA) and 0.05 
wt.% ammonium persulfate (APS, from a 20 wt.% stock in water; Bio-Rad Laboratories), 
then 50 µL aliquots of polymer solution were pipetted onto methacrylate-silanized 
coverslips and topped with untreated coverslips. These reactions were performed on the 
bench at room temperature, with empirically-determined optimal polymerization times of 
22, 20, 19 and 18 minutes for 14.7, 43.1, 83.8 and 135 mM PEGDMA, respectively. At the 
specified times, the gels were immediately moved to 6-well plates (3 gels/well) and 
covered with PBS. The next day, top coverslips were carefully removed with fine forceps. 
To quantify the elastic moduli of the hydrogels directly on the coverslips, a piezo-
controlled linear actuator (Burleigh Inchworm Nanopositioner) was used to bring a 
polystyrene-coated steel cylindrical probe (cross-sectional radius ~ 0.75 mm) into contact 
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with a sample. Upon contact and reproach, the relative displacement, δ, and resulting force, 
P, were measured with a custom-designed load cell (Fig. 4.1a). In addition, the contact 
radius, a, established between the probe and the gel was confirmed to equal the radius of 
the probe with a Zeiss Axiovert 200M microscope (Carl Zeiss, Oberkochen, Germany). 
Tests were conducted at a crosshead velocity of 0.5 μm/s and the total displacement for 
each test was fixed at 30 μm. 
 To quantify the elastic modulus, the compliance, 𝐶 =
𝜕𝛿
𝜕𝑃
, was determined from the 
linear force-displacement curves (Fig. 4.1a), and the modulus, E, determined by [24]: 
𝐸 =
(1 − 𝜈2) 
2𝐶𝑎
{ 1 + 1.33 (
𝑎
ℎ
) + 1.33 (
𝑎
ℎ
)
3
}
−1
 
 where 
𝑎
ℎ
 is the ratio of the contact radius to the thickness of the hydrogel. Fully 
swollen hydrogels are often considered to be in compressible under relevant time scales of 
loading [25], such that the Poisson ratio, v, is typically in the range of 0.4-0.5. We present 
the results in Figure 4.1 as both an effective modulus, 𝐸∗ =
𝐸
1−ν2
, and as a Young’s 
modulus, E, with an estimated Poisson’s ratio of 0.5. 
 
4.3.3 Protein functionalization to hydrogel surfaces 
Two protein cocktails were prepared in PBS (Fig. 4.2): ‘BaM’ (basement 
membrane representation) containing 50% (w/v) collagen IV (recombinant human; Sigma-
Aldrich) and 50% laminin (mouse), and ‘InF’ (inflammatory ECM representation) 
containing 50% monomeric collagen I (rat tail) and 50% fibronectin (human plasma; EMD 
Millipore, Billerica, MA). Glacial acetic acid was added to the InF cocktail at 0.14 vol.% 
to prevent collagen fibril formation. 
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 Hydrated gels were treated with sulfo-SANPAH (0.3 mg/mL in pH 8.5 HEPES 
buffer; ProteoChem, Denver, CO) under UV light for 10 minutes at ~3 in. They were then 
washed with PBS 2x and incubated with 75 µL of cocktail for a 3 µg/cm2 theoretical surface 
concentration. After 20 h, gels were transferred to fresh wells, washed 3x over 30 min in 
PBS, and UV sterilized for at least 30 min prior to cell seeding. 
 
4.3.4 Cell proliferation assays 
We used the common alamarBlue (resazurin [26]) assay to quantify relative cell 
populations. An alamarBlue stock solution was made by adding resazurin sodium salt 
(Sigma-Aldrich) to 0.1 wt.% in PBS and then sterile-filtering with a 0.2 µm filter (Thermo 
Fisher Scientific). The assay was performed by replacing the media on samples with a 
solution of 10% alamarBlue stock and 90% DMEM containing 10% FBS and 1% P/S. The 
sample plates were then incubated at 37°C/5% CO2 for 2 hours, 2 x 100 µL aliquots were 
transferred to 96-well plates and fluorescence measured with a Spectramax M5 microplate 
reader (Molecular Devices, Sunnyvale, CA) using 550 nm (excitation) and 585 nm 
(emission) wavelengths. To assess the impact of soluble factors, ECM composition and 
stiffness on SMC proliferation, HASMCs were seeded at approximately 5,600 cells/cm2 
on samples with Young’s moduli from approximately 40 to 94 kPa in 24-well tissue culture 
plates. 24 hours post-seeding, initial cell adhesion was assessed on a set of technical 
replicates with the alamarBlue assay. The final cell proportions of the remaining technical 
replicates were assayed following phenotype syncing and 96 hours of treatment with either 
differentiation or growth medium, and we have reported these results as the fold-difference 
between the first and final days with 5-6 independent biological replicates per condition.  
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4.3.5 Cell migration assays 
 To assess the impact of soluble factors, ECM composition and stiffness on SMC 
2D motility, cells were sparsely seeded on samples in 12-well plates, synched towards the 
contractile phenotype, then immobilized in the wells of 24-well plates with 5-minute epoxy 
(Devcon, Danvers, MA) and either growth or differentiation medium pipetted into the 
wells. Cell motility was observed with a Zeiss Axio Observer Z1 (Carl Zeiss) inverted 
microscope (5x objective, brightfield; images taken for 12 hours at 15 minute intervals). 
Cell positions were manually tracked with ImageJ [27] using the Manual Tracking plugin 
[28], and we calculated the average velocity, displacement, and chemotactic index of each 
tracked cell by fitting to a random walk model in MATLAB with code provided by Aaron 
Meyers. We have reported the results as the population average velocities and chemotactic 
indices for each condition, from 3-5 independent biological replicates and a minimum of 
100 cells per condition. 
 
4.3.6 Cell invasion assays 
To assess the impact of soluble factors, ECM composition and stiffness on SMC 
invasion into collagen I gels, we performed experiments in 24-well plates, as described 
above, with 40 and 94 kPa Young’s modulus PEG-PC, but immediately after phenotype 
syncing we polymerized collagen I gels on each sample. This was performed by mixing 
either differentiation or growth medium 1:20 with sterile 1 M NaOH (Thermo Fisher 
Scientific), and mixing this solution 1:2 with 3 mg/mL type I collagen (rat tail; Life 
Technologies) for a 2 mg/mL collagen I solution. All solutions were pre-chilled and kept 
on ice. This well-mixed solution was then pipetted over each sample (300 µL/well) and the 
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plates incubated at 37°C/5% CO2 for 5 minutes. After polymerization, 600 µL of warm 
differentiation or growth medium was slowly pipetted onto each collagen I gel and the 
plates returned to the incubator. After 48 hours, the media solutions were very carefully 
aspirated off the gels and replaced with fresh media. After another 48 hours, the samples 
were imaged with a Zeiss Axio Observer Z1 inverted microscope, by taking images with 
30 µm Z-slices at 5x and a 10x objective in brightfield. The approximate depth of invasion 
into the collagen gels was determined manually by counting the number of Z-slices from 
the surface of the PEG-PC gel to the focal plane of invaded cells. We report these results 
as the average cell invasion depth, with a minimum of 3 independent biological replicates 
and 140 cells per condition.  
 
4.3.7 SMC marker Western blotting 
 To assess the impact of soluble factors, ECM composition and stiffness on SMC 
marker expression, we seeded HASMCs at approximately 11,000 cells/cm2 on samples in 
24-well plates and cultured them as described in the preceding sections. Note that, to 
eliminate the possibility that differences in expression are due to differences in time in 
culture, for all media-type comparisons the samples were maintained in culture for the 
same length of time, i.e. in the comparison between serum-starved and TGFβ1 treated 
samples, the TGFβ1 treated samples were serum-starved for 48 hours and TGFβ1 treated 
for 48 hours, whereas the serum starved samples were in serum-free media for 96 hours. 
At various time points, samples were briefly rinsed with ice-cold PBS, and immediately 
lysed, on ice, for 5 minutes with freshly-prepared, ice-cold Tris-Triton lysis buffer 
containing 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
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100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate and freshly-added protease inhibitors 
(cOmplete Mini EDTA-free protease inhibitor tablets, Roche Applied Sciences, Penzberg, 
Germany). To increase total protein concentration, lysis buffer volumes were kept low (< 
100 µL/well) and/or 2-3 replicates of each condition were pooled with the same aliquot of 
lysis buffer. If not to be used that day, lysates were snap frozen in liquid nitrogen and stored 
at -80°C. 
 The protein concentrations of freshly prepared lysates, or previously-frozen lysates 
thawed on ice, were measured with the Pierce BCA protein assay in a microplate format 
(Thermo Fisher Scientific) using a BioTek ELx800 absorbance microplate reader (BioTek, 
Winooski, VT), and the sample protein concentrations normalized by dilution with ice-cold 
Tris-Triton buffer containing freshly-added protease inhibitors. Each sample, typically 
containing 6-10 µg total protein, was then mixed with Laemmli sample buffer (4x; Boston 
BioProducts, Ashland, MA), heated in boiling water for 5 minutes, loaded on 4-20% SDS-
PAGE gels (10 well, 50 µL/lane Mini-Protean® TGX precast gels, Bio-Rad Laboratories) 
along with a lane for the Precision Plus Protein Kaleidoscope protein standard (Bio-Rad), 
and run at 200 V for 30 minutes in SDS-PAGE running buffer (25 mM Tris, 190 mM 
glycine, 0.1% SDS).  
The proteins were then transferred to PVDF membranes in Western blot transfer 
buffer (25 mM Tris, 190 mM glycine, 20% methanol) at 110 V for 90 minutes on ice. After 
transfer, blots were blocked for 2 hours at room temperature, with agitation, using either 5 
wt.% bovine serum albumin (BSA; Sigma-Aldrich) in Tris-buffered saline with 0.1 vol.% 
Triton X-100 (TBS-T) for calponin detection, or in TBS-T containing 5 wt.% nonfat milk 
for smoothelin detection. After blocking, the blots were incubated overnight at 4°C, with 
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agitation, in BSA blocking buffer containing primary antibody to calponin (clone EP798Y, 
1:10000; Abcam, Cambridge, MA), or in milk blocking buffer with primary antibody to 
smoothelin-B (clone H-300, 1:200; Santa Cruz Biotechnology, Dallas, TX). The next day, 
the blots were washed 5x with TBS-T, then incubated with HRP-conjugated secondary 
antibody (anti-rabbit polyclonal, Abcam) in blocking buffer for 2 hours at room 
temperature, with agitation, then washed 5x with TBS-T. Finally, detection was performed 
with enhanced chemiluminescence (ECL) by mixing equal volumes of a solution 
containing 2.5 mM luminol (3-aminophthalic hydrazide, 250 mM stock in DMSO; Thermo 
Fisher Scientific) and 0.396 mM p-coumaric acid (90 mM stock in DMSO, Thermo Fisher 
Scientific) in 100 mM Tris buffer, pH 8.6, and a solution containing 0.018% hydrogen 
peroxide (Thermo Fisher Scientific) in 100 mM Tris buffer, pH 8.6, incubating blots in this 
solution for exactly 1 minute and then imaging with a G:BOX (Syngene, Frederick, MD). 
Finally, the calponin blots were washed 3x with TBS-T and probed for cyclophilin B as an 
internal control (primary Ab from Thermo Fisher Scientific, 1:10000) with the same 
procedure. 
 
4.3.8 Immunofluorescent staining of HASMCs 
To fix cells for immunofluorescent staining immediately following phenotype 
syncing, as well as immediately following phenotype syncing plus 48 hours of treatment 
with differentiation or growth media, samples were rinsed 2x with warm PBS, incubated 
in fresh 4% formaldehyde for 20 minutes, and blocked with AbDil (2% BSA in Tris-
buffered saline with 0.1% Triton X-100, TBS-T) for 1 hour. Calponin was 
immunofluorescently labeled with a primary antibody to calponin (clone EP798Y ; Abcam) 
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and an anti-mouse FITC secondary antibody (Jackson ImmunoResearch Laboratories), or 
smoothelin was labeled with a primary antibody to smoothelin-B (clone H-300; Santa Cruz 
Biotechnology) and an anti-rabbit FITC secondary antibody (Jackson ImmunoResearch 
Laboratories).  F-actin was fluorescently labeled with Alexa Fluor 555-conjugated 
phalloidin (Life Technologies), and cell nuclei were labeled with DAPI (MP Biomedicals). 
Antibody incubations were performed for 1 hour in AbDil, in the dark, and cells were 
thoroughly washed between labeling steps with TBS-T.  Each sample was equilibrated with 
ProLong Gold antifade reagent (Life Technologies) for 5 minutes before imaging. Images 
were taken with a 63x oil immersion objective, on a Zeiss Axio Observer Z1 microscope 
(Carl Zeiss). 
 
4.3.9 Reverse transcriptase PCR to confirm smoothelin expression 
 We confirmed the expression of smoothelin mRNA with reverse transcriptase PCR 
(RT-PCR). HASMCs were grown to confluence on tissue culture plastic in complete 
growth medium, total RNA collected with the GenElute Mammalian Total RNA Miniprep 
Kit (Sigma-Aldrich), and the concentration of RNA measured with a NanoDrop ND-1000 
(Thermo Fisher Scientific). We then mixed 1 µg of total RNA with RNasin Plus (Promega), 
oligo(dTs) and RNase-free water according to the manufacturer’s instructions, denatured 
secondary structures with heating at 70°C for 5 minutes, chilled on ice for 5 minutes, and 
finally added a reverse transcriptase master mix (1x reaction buffer, RNasin Plus, dNTPs 
and RevertAid Reverse Transcriptase, Thermo Fisher Scientific) to the total RNA and 
incubated at 42°C. After 60 minutes, the reaction was heat inactivated at 70°C for 10 
minutes. The reaction product was amplified with standard PCR using JumpStart Taq DNA 
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polymerase (Sigma-Aldrich) and primers designed against the SMTN-B gene (accession 
Y13492, forward: CACTCATGTCACCAGCTTCAG, reverse: 
CTCTGATCCAGCATCTTGTCC). Finally, the PCR reaction product was separated on 
an agarose gel along with a nucleotide ladder (New England BioLabs, Ipswich, MA) and 
visualized with an InGenius UV gel imager (Syngene).  
 
4.3.10 Characterization of HASMC morphology 
 To assess the impact of soluble factors, ECM composition and stiffness on 
spreading area and morphology, HASMCs were sparsely seeded on ECM-coated PEG-PC 
samples and, after 48 hours of treatment with the specified media type, washed with warm 
PBS and fixed for 20 minutes with warm 4% formaldehyde in PBS, at room temperature. 
The fixed samples were then washed 3x with PBS, then incubated with Cellomics Whole 
Cell Stain Blue (Thermo Fisher Scientific) according to the manufacturer’s instructions, 
for 90 minutes. The samples were again washed 3x with PBS, then imaged with a Zeiss 
Axio Observer Z1 inverted microscope with a DAPI filter and a 10x objective. Finally, 
isolated cells were manually traced in ImageJ, and the areas, aspect ratios (AR) and other 
properties measured with the built-in “Measurement” tool. We report these results as cell 
averages from a minimum of 3 independent biological replicates and 100 cells per 
condition. 
 
4.3.11 Cell signaling time course with MAGPIX multiplex analysis 
 To assess the impact of soluble factors, ECM composition and stiffness on several 
major intracellular signaling pathways, sample lysates were collected during 3 separate 
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time courses (Fig. 4.8) and analyzed using a MAGPIX instrument (Luminex Corporation, 
Austin, TX) and a 9-plex magnetic bead cell signaling multiplex assay kit (48-680MAG; 
Merck Millipore, Billerica, MA) to simultaneously measure the activities of the following 
phospho-proteins: CREB (pS133), ERK (pT185/pY187), NFκB (pS536), JNK 
(pT183/pY185), p38 (pT180/pY182), p70 S6K (pT412), STAT3 (pS727), STAT5A/B 
(pY694/699), and Akt (pS473). Lysis was performed with MAGPIX lysis buffer, 
containing 50 mM Tris-Cl, pH 7.1, 1% NP-40, 10% glycerol, and 150 mM NaCl, with 
freshly-added phosphatase inhibitors (Phosphatase Inhibitor Cocktail II, 2x working 
concentration; Boston BioProducts) and protease inhibitors (cOmplete Mini, EDTA-free), 
plus (all from Thermo Fisher Scientific) additional sodium pyrophosphate (1:100 from 0.1 
M stock), β-glycerophosphate (1:40 from 1 M stock), phenylmethanesulfonyl fluoride 
(1:500 from 0.5 M stock), leupeptin (1:1000 from 10 mg/mL stock) and pepstatin A 
(1:1000 from 5 mg/mL stock). To minimize protease and phosphatase activity, lysis and 
sample handling was performed in a 4°C environment. At each time point, sample plates 
were rinsed briefly with ice-cold PBS, put on ice and lysed with buffer for 5 minutes. 
Sample lysates were then pipetted over the gel surface several times, collected in chilled 
microcentrifuge tubes, snap frozen in liquid nitrogen, and stored at -80°C. On the day of 
each MAGPIX experiment, samples were thawed on ice, protein levels quantified with the 
Pierce BCA assay as described above, and concentrations normalized with fresh lysis 
buffer. The MAGPIX assays were then performed in accordance with the kit 
manufacturer’s instructions. We report these results as the average net mean fluorescence 
intensity (MFI) of 2-4 biological replicates. 
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4.3.12 Kinase inhibition experiments 
 To assess how inhibition of 4 kinases of interest modulate SMC marker expression, 
we seeded HASMCs on 40 and 94 kPa ECM-coated PEG-PC samples at approximately 
11,000 cells/cm2, as described above. After 48 hours of serum-starvation, kinase inhibitors 
were co-administered during TGFβ1 treatment. We inhibited Akt with the allosteric 
inhibitor sc-66 [29] at 1 µg/mL (20 mg/mL stock in DMSO; Abcam), FAK with FAK 
inhibitor 14 [30] at 100 µM (100 mM stock in DMSO; Merck Millipore), and PI3K with 
LY294002 at 50 µM (50 mM stock in DMSO; Merck Millipore). With the exception of 
FAK inhibitor 14, inhibitors were present during the first hour after the media change, and 
then replaced with inhibitor-free media. FAK inhibitor 14, however, was kept in the media 
during the entire 48 hours. After 48 hours, samples were lysed with Tris-Triton buffer and 
Western blotted as described above.  
Proliferation experiments in differentiation medium were performed as described 
above with inhibitors to Akt or ERK (FR180204 at 20 µM final concentration; Sigma-
Aldrich) administered during the first hour of differentiation medium stimulation, then 
additionally for one hour during the medium change at 48 hours.  
 
4.3.13 Statistical analysis 
Statistical analysis was performed using Prism v5.04 (GraphPad Software, La Jolla, 
CA). Data are reported as mean ± standard error, unless otherwise noted.  Statistical 
significance of the difference between pairs of means was evaluated by computing P-values 
with unpaired Student's t-tests. P ≤ 0.05 is denoted with *, ≤ 0.01 with **, ≤ 0.001 with 
*** and ≤ 0.0001 with ****; P > 0.05 is considered not significant ('ns'). 
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4.4 Results 
4.4.1 PEG-PC mechanical properties and in vitro microenvironments 
 We used indentation to quantify the effective modulus of samples that were 
prepared on glass cover slips identically to those used in biological experiments. As 
expected for a linear elastic material loaded with a flat punch geometry, the relationship 
between force and displacement is linear for all compositions tested (Fig. 4.1a). 
Interestingly, the PEG-PC mechanical properties measured in this way were rather 
different than those described in Chapter 2 [9]. It is unexpected that different testing 
methods would produce such large differences, so we suspect the softer gels may be due 
to the APS and TEMED curing, differences in curing times (which were optimized for 
adhesion to cover slips), or surface effects from curing between cover slips. There was no 
significant dependence on displacement rate as observed from the load-displacement 
response at different crosshead velocities (v = 0.1 µm/s and 0.5 µm/s, not shown).  For ease 
of comparison to the more commonly used Young’s modulus, we estimated a Poisson ratio 
of 0.5 to translate these effective moduli to Young’s moduli. 
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Figure 4.1: in situ PEG-PC contact mechanics testing 
(a) PEG-PC hydrogel elastic modulus on glass coverslips was measured with contact 
mechanics by bringing a cylindrical probe into contact with the gel surface and measuring 
the force, P, versus displacement, δ. Data is plotted with compressive force and 
displacement values being positive. (b) The effective modulus, E*, was measured over a 
range of [PEGDMA] concentrations from a minimum of three samples per condition and 
used to calculate a Young’s modulus, E, using an estimated Poisson’s ratio of 0.5. 
Calculated and estimated moduli are plotted versus [PEGDMA]. (c) Tabulated PEG-PC 
data. 
 
To create a biomaterial environment that captured key biochemical and physical 
environments, we coupled the tunable mechanics of the PEG-PC gel system with ECM 
proteins representative of the proteins to which SMCs are attached in a healthy medial layer 
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(basement membrane, or BaM) or those representative of an inflammatory plaque 
(inflammatory or InF) (Fig 4.2a). These insoluble cues were combined with soluble factors 
also commonly found in these two scenarios. Unless otherwise noted, in all experiments 
we also ‘synced’ cell populations towards the contractile phenotype with a series of media 
changes prior to stimulation with growth or differentiation mediums (Fig. 4.2b). 
 
 
Figure 4.2: Description of in vitro model and general experimental design 
(a) Two ECM protein mixtures representative of the major integrin-binding adhesive 
proteins found in an intact arterial media (BaM) and an atherosclerotic plaque (InF) were 
used in combination with two mixtures of soluble factors (differentiation and growth 
medias) and PEG-PC substrates with Young’s moduli 40-94 kPa to model the changes that 
typically occur during the progression of atherosclerosis. (b) Time line of phenotype 
syncing protocol performed for all experiments (unless otherwise noted).  
 
4.4.2 alamarBlue accurately measures differences in HASMC number 
 We confirmed that the alamarBlue assay is suitable for use in this cell type by 
seeding serial dilutions of cells on plastic and collagen III-coated PEG-PC and performing 
the alamarBlue assay after 24 hours of adhesion. We report that, with a 2 hour incubation, 
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this assay produces an excellent standard curve with respect to the number of seeded cells, 
on both PEG-PC and tissue culture plastic (Fig. 4.3), linear regression R2 = 0.9970 and 
0.9869, respectively). In the same experiment, we also compared against the popular, and 
much more expensive, CellTiter96 AQueous One (Promega) assay, but got subpar results 
(R2 = 0.8788 and 0.7711 for plastic and gels, respectively. Data not shown). We conclude 
that the very low cost and excellent linearity of the alamarBlue assay in the range of cell 
numbers used with these proliferation experiments make it a suitable choice for this cell 
type.  
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Figure 4.3: alamarBlue produces an excellent cell number standard curve 
We demonstrated the linearity of the alamarBlue assay on TCPS and PEG-PC by seeding 
serial dilutions of HASMCs and performing the alamarBlue assay 24 hours later. 
Representative example shown. Note that it is not possible to compute an actual cell 
number without creating a standard curve for every proliferation assay and assuming that 
all seeded cells adhere and do not proliferate.   
 
4.4.3 Proliferation is primarily regulated by ECM composition 
We quantified proliferation of contractile SMCs on gels from 40 to 94 kPa, after 4 
days of culture in growth and differentiation media (Fig .4.4). Substrate modulus had a 
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positive effect on cell proliferation in differentiation medium, and with the BaM 
configuration in growth medium.  This effect was most pronounced with the combination 
of the BaM ECM and differentiation medium (Fig. 4.4b). Substrate modulus had a less 
pronounced effect on proliferation on the InF configuration with growth medium, and 
played no significant role with differentiation medium. We infer that the ECM-specific 
responses are mediated by differences in integrin activation, in agreement with a previous 
study comparing fibronectin, collagen, and laminin-coated gels [31].  Heparin is well 
known to inhibit the effects of certain GFs on SMC proliferation [32,33], further supporting 
this hypothesis. However, the several soluble factors in the growth medium are apparently 
capable of overriding any growth inhibitory effects mediated by the BaM configuration, 
resulting in no differences in proliferation with this condition. Furthermore, modulus has a 
large effect on cell population from 40 to 60 kPa (with the exception of InF ECM in 
differentiation medium), but the effect is not further enhanced with increasing modulus. 
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Figure 4.4: SMC proliferation is modulated by stiffness, ECM, and soluble factors 
SMC proliferation was measured as a function of hydrogel modulus (x-axis) on both ECM 
configurations (BaM, ●, and InF, ■). The results are reported here as the fold-change in 
cell populations between day 1 (24 hours post-seeding) and day 9 (post-syncing and 96 
hour stimulation with growth (a) or differentiation (b) medias). In (a), colored *’s denote 
the difference in proliferation is significantly different than the softest condition. In (b), 
black *’s indicate a significant difference in proliferation between ECM compositions at 
that stiffness, and blue *’s indicate significant difference from stiffer BaM conditions. 
Error bars are ± SEM with N = 5-6 independent biological replicates. 
 
4.4.4 ECM composition is the most significant driver of 2D and 3D motility 
 As models of the early stages of SMC invasion into a developing plaque, we 
evaluated both the 2D random migration and 3D invasiveness of SMCs as modulated by 
ECM composition, soluble factors, and stiffness (Fig. 4.5). We found that ECM 
composition and soluble factors have a very significant impact on average cell speeds and 
migration directionality (Fig. 4.5a-b). SMC speed has been reported as biphasic with 
respect to substrate modulus [5], which we did not observe in our initial experiments; 
however, after introducing an even softer condition (11 kPa), we found that cells on BaM 
in differentiation medium migrated much slower than the other stiffnesses, demonstrating 
that the biphasic regime for BaM and differentiation medium was not spanned in our 
original experiments. Unexpectedly, the average speed on BaM is significantly higher than 
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on InF with either medium supplement, but the chemotactic index on InF is higher. This 
latter result indicates that cells on BaM move erratically and non-directionally. Growth 
medium generally increased both random migration speed and the chemotactic index on 
both ECM configurations.  
Given these surprising results on 2D surfaces, we hypothesized that integrin 
binding was significantly influencing cell adhesion, and could therefore impact 3D 
invasion as well. With a collagen gel invasion assay, we found that invasion depth is greater 
with SMCs from the BaM ECM in growth medium, with a modest increase in invasion 
depth on the soft versus stiff substrates (Fig. 4.5c-d). Invasion depth in differentiation 
medium was overall shallow, but greater for the soft BaM condition. Given the observed 
weaker adhesion/spreading on BaM, it is possible that invasion depth is greater due to ease 
of detachment; however, since the SMCs are given 4 days to invade the collagen matrix, 
BaM may also induce phenotypic changes that affect the SMCs long after leaving the BaM 
surface. 
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Figure 4.5: SMC motility is modulated by ECM and soluble factors 
SMC average migration speed (a) and chemotactic index (b) during stimulation with 
growth and differentiation mediums (solid and dashed lines, respectively) was quantified 
as a function of Young’s modulus (x-axis) on both ECM configurations (BaM, ●, and InF, 
■). Error bars are ± SEM with N > 100 cells and at least 3 independent biological replicates. 
Statistical significance is not labeled because all discernible differences have p-values < 
0.05 or better. In a collagen gel invasion assay, SMCs were seeded on the softest (c) and 
stiffest (d) conditions with BaM and InF ECM configurations (blue and red, respectively) 
and with both growth and differentiation mediums as chemoattractants (x-axis). Tukey box 
plot with N > 100 cells per condition and 3-4 independent biological replicates, except for 
2 replicates on soft BaM in differentiation medium. 
 
4.4.5 SMC size and morphology is primarily dictated by ECM composition 
 Since SMC phenotype is reported to be correlated with shape and size [34], we 
quantified cell morphology on our various surfaces (Fig. 4.6). We found that cells are 
approximately 2-3-fold larger in area on InF compared to BaM (Fig. 4.6a), consistent with 
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a synthetic phenotype on these inflammatory proteins. Average cell aspect ratio (AR) was 
used to evaluate the ‘spindle’-like shape of SMCs, with high ARs indicating an elongated, 
spindle-like morphology, indicative of the contractile phenotype. We found that the 
average cell AR has little dependence on modulus or ECM composition after syncing (Fig. 
4.6b), which is further validation that this priming step does chemically “sync” the 
otherwise heterogeneous cells into a consistent, differentiated cell population, even though 
they are seeded onto different stiffness gels with different integrin-binding conditions. 
Remarkably, we observed that the average AR of cells on BaM in growth medium increases 
with substrate modulus, and it is higher overall than on InF with either growth or 
differentiation media stimulation (Fig. 4.6b). Thus, while aspect ratios are synced during 
1 treatment, the contractile phenotype appears to be better maintained, at least with 
respect to cell morphology, on stiff gels with basement membrane proteins, regardless of 
the ensuing medium conditions. 
 
117 
 
 
Figure 4.6: SMC adhesion and morphology is dictated by ECM composition 
(a,b) Cell spreading area (a) and aspect ratio (b) were quantified with manual tracing and 
ImageJ’s ‘Measurement’ tool as a function of hydrogel modulus (x-axis) and ECM 
composition (BaM, ●, and InF, ■) after phenotype syncing (light colored dashed lines) and 
stimulation with growth or differentiation mediums for 48 hours (solid and dashed lines, 
respectively). Error bars are ± SEM with N > 100 cells and 3 independent biological 
replicates. Statistical significance is not labeled because all discernible differences have p-
values < 0.05 or better.  (c) Immunofluorescent staining of vinculin (green), actin stress 
fibers (orange), and nuclei (DAPI)  of SMCs on the softest and stiffest substrates with both 
ECM compositions in growth medium after 48 hours of culture. Scale bar is 50 µm. 
 
4.4.6 Soluble factors and modulus significantly affect marker expression 
To connect SMC motility and proliferation to prototypical markers of SMC 
differentiation, we evaluated the expression of calponin and smoothelin via Western 
blotting (Fig. 4.7a). Synthetic SMCs secrete ECM and are classically characterized by the 
downregulation of several contractile phenotype-associated marker proteins (caldesmon, 
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calponin, SM-MHC, smoothelin and more [35–37]).  These proteins interact with the actin 
cytoskeleton and have roles in regulating actomyosin contractility, and are therefore 
involved in mechanotransduction. In agreement with previous reports [38], we found that 
treatment with TGFβ1 during the syncing steps increased expression of both calponin and 
smoothelin after serum starvation. The differentiation medium supplement (SMDS) is 
intended to promote SMC differentiation, while the growth medium induces proliferation 
and dedifferentiation. In agreement with these expectations, we found that, relative to 
TGFβ1 treatment, calponin expression is modestly up- and down-regulated by 
differentiation and growth medium, respectively (Fig. 4.7a, top). Smoothelin expression, 
however, increases with differentiation and further increases with growth medium (Fig. 
4.7a, bottom). Calponin expression increases on stiff substrates and InF with differentiation 
medium, but is not affected by stiffness in the other contexts, whereas smoothelin 
expression is enhanced on stiff substrates with TGFβ1 and differentiation medium, or with 
growth medium on InF. Any effect of stiffness was most pronounced on InF, and 
expression of both markers was greater on InF than BaM on soft substrates, but otherwise 
there was little-to-no difference in expression between the integrin-binding conditions. 
These results, in combination with our proliferation and migration results (Figs. 4.4, 4.5), 
directly contradict the notion that SMC marker expression and behaviors indicative of the 
synthetic phenotype are inversely related. 
Given the reported scarcity of smoothelin in cultured SMCs [35], we visualized 
actin fibers and calponin or smoothelin with immunofluorescence (Fig. 4.7b). These results 
confirmed antibody specificity for stress-fiber localized proteins, and also that smoothelin 
co-localizes to the nucleus [39]. We further confirmed expression of the smoothelin-B 
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mRNA with reverse transcriptase PCR in SMCs grown on TCPS in FBS-containing growth 
medium (Fig. 4.7c). 
 
 
Figure 4.7: SMC marker expression is more dependent on soluble factors than ECM 
(a) Representative Western blots for calponin (top) and smoothelin (bottom) after each 
syncing step and stimulation with growth or differentiation mediums. SS: Serum-starve, 
TGF
growth medium. Internal control bands (labeled ‘i’) for normalization are cyclophilin B. 
(b) Immunofluorescent staining of calponin (top) and smoothelin (bottom) in green with 
actin (red) and DAPI (blue). Scale bar is 20 µm. (c) Reverse transcriptase PCR to confirm 
expression of SMTN-B mRNA.  
 
4.4.7 FAK controls SMC plasticity, in part through PI3K/Akt  
To understand the possible signaling mechanisms driving the phenotypic diversity 
of the SMCs we had observed thus far, we quantified the activation of several major 
signaling proteins during adhesion, TGFβ1 treatment, and stimulation with differentiation 
medium, with a phospho-protein multiplex assay (Fig. 4.8). We observed characteristic 
spikes in phosphorylation of ERK and Akt on each modulus tested, and phosphorylation 
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was generally higher on the InF configuration.  We detected little to no phosphorylation of 
1 stimulation (not shown), and again ERK peaked at early time points 
and was enhanced by the InF configuration.  Interestingly, ERK showed higher 
phosphorylation on the stiffer hydrogel during TGFβ1 stimulation (Fig. 4.8b).  Finally, we 
saw opposing trends in Akt and ERK phosphorylation during stimulation with 
differentiation medium (Fig. 4.8c).  Akt activity was initially low, suggesting that 
differentiation medium does not directly activate Akt, but by 24 hours the phosphorylation 
level was significantly greater, with a positive influence from stiffness and the InF ECM. 
However, ERK had the characteristic early spike in activity which subsides to a baseline 
after approximately 1 hour, and activity was once again greater on the InF ECM without 
being affected by substrate stiffness. 
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Figure 4.8: Cell signaling time courses 
(a-c) Phosphorylation of Akt and ERK, when occurred, are plotted as a function of time 
(x- 1 stimulation (b), and 
stimulation with differentiation medium (c). Error bars are ± SEM from N = 2-4 
independent biological replicates. 
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We then performed experiments with inhibitors to signaling proteins that are 
associated both with Akt and integrin activity to draw a connection between our observed 
SMC phenotypes and ECM composition (Fig. 4.9). We inhibited FAK, PI3K and Akt with 
small molecule pharmacological inhibitors, and found that FAK was the strongest upstream 
driver of SMC differentiation on all conditions. In fact, inhibition of FAK completely 
abrogated expression of both calponin and smoothelin (Fig. 4.9a). However, while 
inhibition of PI3K or Akt reduced expression of calponin, it had little to no effect on 
smoothelin expression. Interestingly, though we did not find any substantial differences in 
expression between the two ECM configurations, it is of note that cells on InF remained 
well-spread and appeared relatively normal over 48 hours, but cells on the BaM 
composition underwent rounding and detachment, prohibiting us from obtaining data for 
the 40 kPa BaM condition with Akt or FAK inhibitors. These results imply that regulation 
of smoothelin and calponin expression diverges downstream of activated FAK, though it 
appears that PI3K and Akt may still have role. We also performed proliferation 
experiments with ERK and Akt inhibitors in differentiation medium, but Akt inhibition for 
96 hours caused total cell loss through detachment and/or apoptosis on both ECM 
configurations, and the effects of ERK inhibition were inconsistent and differences were 
statistically significant (Fig. 4.9b). Despite this, we still suspect a role for ERK in mediating 
SMC proliferation in our model, but we speculate that the inhibitor was ineffective because 
the working concentration was not verified and optimized. In addition, there are few or no 
reports of FR180204 being used with SMCs, suggesting we may have had different results 
with the more commonly-used inhibitor PD98059. 
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Figure 4.9: Effects of kinase inhibition on SMC marker expression and proliferation 
(a) During the final phenotype syncing step (TGFβ treatment for 48 hours), inhibitors to 
PI3K (50 µM LY294002), Akt (1 µg/mL sc-66), and FAK (100 µM inhibitor 14) were co-
administered for the first hour (with the exception of FAK inhibitor 14, which was present 
for the duration), and after 48 hours lysates were collected and subsequently Western 
blotted for calponin and smoothelin. Internal control bands are cyclophilin B. Note that 
Akt and FAK inhibition for 48 hours resulted in complete loss of cells on the soft BaM 
condition and thus we were unable to examine expression under those conditions. (b) 
Proliferation experiments with differentiation medium were performed as described 
previously, with the addition of inhibitors to Akt (1 µg/mL sc-66) and ERK (20 µM 
FR180204). Error bars are ± SEM with N = 3 independent biological replicates. 
 
4.5 Discussion 
SMCs are observed to rapidly convert from the contractile to the synthetic 
phenotype when removed from the in vivo microenvironment and cultured on plastic. This 
phenotype plasticity has been heavily studied due to similarities between the synthetic 
phenotype observed in vitro and that of the SMCs found in atherosclerotic plaques. The 
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presence of synthetic SMCs in atherosclerosis is a maladaptive consequence of the 
phenotype plasticity necessary for SMCs during development and wound healing, which 
must be capable of phenotype switching for maintaining vascular wall integrity 
(contractile) and for vascular wall remodeling during development, growth, and normal 
wound repair (synthetic). Inspired by the role of SMCs in vascular mechanics, many groups 
have investigated the effects of various types of mechanical stimuli on SMC phenotype, 
including oscillatory flow [40], stretch [41–43], interstitial flow [44,45], and laminar versus 
nonlaminar flow [46]. However, most previous in vitro studies of SMC phenotype use 
relatively simple models, and we believe many new insights may be gained by trying to 
more closely match the in vivo microenvironment with more complex in vitro models. 
With this approach in mind, we have designed a 2D biomaterial system that reflects 
several major, physicochemical changes in the in vivo extracellular microenvironment that 
are purported to occur during the progression of atherosclerosis and restenosis. Our 
observations demonstrate that interplay between the various components of a complex 
microenvironment can modulate phenotype and behavior in complicated, unexpected 
ways. In fact, many assumptions from the SMC literature on/in other in vitro environments 
do not hold here, which we suspect is due the focus on single physicochemical cues, instead 
of the combinatorial approach we have taken here. 
One of the major failed assumptions revealed by our data is that expression of SMC 
marker proteins is not inversely related to proliferation as commonly reported 
[15,17,20,47]. In fact, expression of calponin, and smoothelin to a lesser extent, was overall 
greater with inflammatory than basement membrane proteins on soft substrates. In contrast, 
proliferation was significantly greater on InF than BaM in differentiation medium, and 
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unchanged in growth medium (Figs. 4.4, 4.7). This data suggests that the signaling 
pathways regulating SMC proliferation and marker expression are not strictly antagonistic, 
or possibly even coupled at all. However, the proliferation trends in differentiation medium 
indicate that the effects of soluble factors on proliferation in these contexts are modulated 
by integrin activity [48,49].  
In contrast, soluble factors had unexpected effects on marker expression that were 
only modestly modulated by ECM composition – applying TGFβ1 to serum deprived cells 
significantly increased expression of both markers, as expected [38,50], and calponin was 
upregulated and downregulated by differentiation and growth medias, respectively, as 
expected. However, smoothelin expression was slightly increased with either supplement, 
suggesting differences in regulation. Stiffness consistently positively affected expression 
of both proteins, which is counterintuitive but in agreement with prior reports [6,7,51].  
In agreement with expected effects of these ECM proteins on SMC phenotype, we 
found that both supplements induced a contractile, spindle-shaped morphology on BaM 
and a large, rhomboidal shape associated with the synthetic phenotype [52,53] on InF (Fig. 
4.6). Remarkably, these traits did not correspond to differences in expression of calponin 
or smoothelin, despite their purported status as components of the SMC contractile 
apparatus. Though a spindle shape is typically associated with contractile phenotype and 
marker expression, they are not strictly coupled [54], which our data corroborates. 
Conversely, we have frequently observed the so-called “hill-and-valley” pattern of cell 
adhesion with TGFβ1 treatment on the BaM composition (Fig. 4.10c-d) which is usually 
associated with SMCs cultured in vitro, and hence the synthetic phenotype. Other groups 
have reported similar results with TGFβ1 treatment on plastic [55] and with prolonged 
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serum-deprivation [56]. Lending further support to veracity of our results is the similarity 
of SMC morphologies on BaM treated with growth or differentiation medium to those 
observed on Matrigel [57], which is comprised primarily of collagen IV and laminin. 
 
 
Figure 4.10: SMC morphology is dictated by ECM composition and soluble factors 
Despite little or no difference in contractile marker expression between the BaM and InF 
ECMs, we observed major differences in morphologies after stimulation with growth or 
differentiation medium, including a spindle-like shape (high AR, Fig. 4.6b) on BaM (a, 94 
kPa BaM after growth medium stimulation), and rhomboidal morphologies on InF (b, 80 
kPa InF after differentiation medium stimulation). Conversely, while differences in AR 
were negligible immediately following phenotype syncing, we consistently observed the 
synthetic phenotype-associated “hill-and-valley” morphology on the BaM ECM (c), but 
not on InF (d, both on 94 kPa substrates). Scale bars are 200 µm. 
 
Of equal interest is the observation that migration and invasion characteristics are 
disconnected from SMC marker expression. However, upon further reflection, the BaM 
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and growth medium condition models the process of detachment from the basement 
membrane and migration towards chemoattractants in a developing plaque (Fig. 4.5c-d). 
Thus, we speculate that SMCs in this model may be reflective of an invasive phenotype 
characteristic of the early stages of atherosclerosis. Finally, our initial experiments showed 
that the effect of stiffness on 2D migration speed did not follow the previously reported 
biphasic trend in vitro [5]. We initially explained this by our combinatorial protein 
approach, as this previous study was done on fibronectin alone, and collagen IV has been 
previously reported to strongly enhance SMC motility relative to the other ECM proteins 
used here [58]. We investigated this further by performing additional migration 
experiments with BaM on 11 kPa PEG-PC in differentiation medium, and possibly 
identified the range of elastic moduli over which SMCs migrate biphasically in this 
microenvironment. 
These and our proliferation results are counter to the oft-repeated notions that SMC 
behaviors associated with atherosclerosis (proliferation, migration, a rhomboidal 
morphology) are inversely related to SMC marker expression, but from our work and other 
reports we now know that the relationship between marker expression and phenotype is 
highly complex. Numerous factors are likely to affect these characteristics, including 
species of origin, cell density, cell age, and anatomical origin. For instance, coincident 
proliferation and contractile marker expression has been reported in neonatal rat SMCs 
[59], in developmental contexts [60–62], in rat SMCs of different ages and from intimal 
hyperplasia [54], and even in human SMCs exposed to TGFβ1 in vitro [17]. Conversely, 
while synthetic SMCs in advanced atherosclerotic or restenotic lesions express very low 
levels of marker proteins [63], and SMCs in lesions generated by the commonly used rat 
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balloon-injury model are proliferative [64], this does not necessarily imply they are 
proliferative in lesions in humans [65].  
Synthetic SMCs are also typically found to be more migratory [34] and invasive, 
but we find large differences in migration speed and invasion depth between the ECM 
compositions, despite there being little difference in differentiation marker expression. We 
conclude from this series of experiments that the relationship between differentiation 
markers and phenotypic characteristics is highly dependent on the physicochemical 
context, and it would be unwise to consider the previously reported correlations between 
markers and behaviors as hard and fast rules. 
Measurement of several signaling protein activity levels over time implicates Akt 
and ERK1/2 signaling pathways in regulating these phenomena, the activities of which are 
overall greater on InF than BaM (Fig. 4.8). Increased stiffness also enhanced signaling 
under certain conditions, but relatively modestly. We were surprised to not detect any p38 
or JNK activity, which have reported roles in SMC migration [66,67], proliferation [67], 
and the response to TGFβ1 [50,68]. However, these studies are themselves contradictory 
[66,67], and so we propose that differences in cell types and contexts explain the lack of 
p38 and JNK activity in our model.  
This analysis was followed up with kinase inhibition experiments to identify 
potential connections between cell signaling pathways and integrins/focal adhesion 
complexes.  The effects of Akt and FAK inhibitors were similar on soft BaM during TGFβ1 
treatment, with total loss of cells by 48 hours, but PI3K inhibition only caused significant 
rounding. Cell rounding was also dramatic with all inhibitors on stiffer BaM, but cells were 
not completely detached. Remarkably, inhibitors had little visible effect with InF during 
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TGFβ1 treatment, with the interesting exception that FAK inhibition dramatically reduced 
cell-cell contacts (not shown). 
We also measured the effect of kinase inhibition during TGFβ1 treatment on marker 
expression and, despite apparently significant effects on the actin cytoskeleton and/or 
adhesion structures, were surprised to find little relation between markers and 
detachment/rounding. The most intriguing finding is that FAK inhibition completely 
abrogates expression of both markers, implicating FAK as a key regulator of contractile 
marker expression in 2D. Furthermore, expression of calponin and smoothelin appear to 
be regulated by distinct, but possibly overlapping signaling pathways that diverge 
downstream of FAK. This conclusion is derived from the finding that smoothelin is 
modestly affected by PI3K inhibition, but barely affected by Akt inhibition, whereas 
calponin is strongly downregulated by inhibition of either on BaM. On InF, however, 
calponin is more strongly regulated via Akt than PI3K, which suggests that Akt may be 
activated through integrin-linked kinase (ILK) independently of, or in addition to PI3K 
[69]. 
The likely explanation of how integrin binding in our system regulated stiffness 
sensitivity and sensitivity to the medium conditions is the crosstalk between integrin 
binding and colocalized growth factor receptors (GFRs). Numerous studies (for review, 
see [70]) have reported a concomitant increase in migration and proliferation after 
treatment with soluble factors or mechanical stimulation, and our data agrees with this 
notion. However, it has long been hypothesized that migration and proliferation of 
synthetic SMCs in atherosclerosis are temporally distinct phenomena [71,72]. We believe 
this seeming contradiction between in vitro data and physiological intuition is an 
130 
 
illustrative example of the limitations necessarily imposed by simpler models. Our data 
indicates that, as the ECM surrounding SMCs changes from a basement membrane 
composition to that found in a plaque, there is a switch from migratory behavior to a high 
rate of proliferation. This data altogether is in vitro evidence that proliferation and 
migration may be inversely related with respect to particular ECM compositions, a 
conclusion that fits well with our understanding of the pathology of atherosclerosis.  
From our data and previous work, we propose hypothetical signaling mechanisms 
in Figures 4.11 and 4.12 that may explain the impact of ECM composition on SMC 
phenotype and behaviors, and how these processes are modulated by soluble factors. As 
described above, our inhibitor experiments indicate that FAK regulates the expression of 
SMC markers, and suggest that calponin and smoothelin regulation may diverge 
downstream of FAK. These experiments also indicate that calponin expression may be 
mediated primarily via PI3K/Akt on BaM and ILK/Akt on InF, whereas smoothelin may 
be regulated via disparate, or possibly partially overlapping pathways. We additionally 
propose that activation of different integrin heterodimers – most likely αVβ3 on InF and 
α2β1 on BaM – well explains the physiologically relevant phenomena we observed. The 
much greater spreading area and slower migration of SMCs on InF, as well as a higher 
prevalence of stress fibers and vinculin-rich focal adhesions, is an indicator of significant 
FAK autophosphorylation [73], which in turn recruits and activates c-Src and enhances 
overall FAK signaling [74]. In fact, β3 integrin itself provides Src homology 2 (SH2) 
binding domains for direct association of c-Src independent of actin and focal adhesion 
assembly [75]. The higher prevalence of these signaling moieties on InF may lead to greater 
proliferation by accumulated signaling through the c-Src/ERK1/2 and/or FAK/ILK/Akt 
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pathways, and greater spreading through FAK-mediated enhancement of RhoA/ROCK and 
stress fiber formation. In contrast, while α2β1 integrin activation on BaM may generate 
many of the same signaling motifs [48], the weaker adhesion we observed suggests less 
FAK/c-Src signaling, resulting in dampened proliferation. 
We also propose a mechanism to explain our observed ECM-controlled switch from 
a migratory to a proliferative phenotype. Prior work with fibroblasts revealed that these 
cells are motile and proliferative at low and high concentrations of PDGF, respectively, a 
change that appears to be mediated by switching between clathrin-mediated endocytosis 
(CME) and raft/caveolin-mediated endocytosis (RME) of the PDGF receptor [76]. We 
hypothesize that changes in integrin activation could facilitate a similar mechanism in 
SMCs. In fact, SMC binding to fibrillar collagen via α2 integrin has been shown to inhibit 
cholesterol biosynthesis [77], which impairs RME and would likely inhibit proliferation. 
Heparin has also been shown to induce it’s anti-proliferative effects, in part, via inhibition 
of RME and ligand-less EGFR activation [78], which may be partially responsible for the 
suppressed proliferation of SMCs on InF in differentiation medium. Other evidence for this 
hypothesis in the literature include a report that insulin signaling in primary adipocytes is 
RME-dependent [79], as is the mitogenic effect of PDGF-BB on human bladder SMCs 
[80]. 
This proposal also fits well with the finding that migration is random and non-
directional on BaM, because CME is responsible for rapid, localized recycling of GFRs at 
the plasma membrane that enables a fast cellular response to transient microgradients of 
chemoattractants [81]. The adhesion properties on BaM also suggest faster turnover of 
FAs, which is likely to support rapid migration on soft substrates. This latter mechanism 
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would seem to also apply to α2β1 integrin binding to monomeric collagen I on InF, but this 
is likely mitigated by the additional presence of fibronectin, which has been found to 
dramatically increase phosphorylation of paxillin [82], decrease migration, and increase 
spreading [83].  
Of potentially major significance is that the association between RME and 
mitogenic signaling provides yet another plausible mechanism by which statins exert their 
atheroprotective effects. Statins are specific inhibitors of HMG-CoA reductase, a rate-
controlling enzyme in the cholesterol biosynthetic pathway, and therefore reduce 
cholesterol concentrations in the plasma membrane and inhibit receptor signaling by 
inhibiting RME [84]. Another side effect of disrupting this pathway is impairment of 
protein prenylation, which is a requirement for plasma membrane localization of Ras 
superfamily members [85], and is likely one way how statins inhibit proliferation (Ras) 
and disrupt actin dynamics/migration (Rho) [86].  
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Figure 4.11: Proposed integrin-mediated signaling mechanisms on BaM ECM 
On the BaM ECM, we predict that specific signaling motifs driven by integrin-binding – 
with α2β1 integrin as a prime candidate – induce a migratory and invasive phenotype with 
low proliferative capacity. We hypothesize that a migratory phenotype is favored on BaM 
due to weak adhesion, high focal adhesion turnover, and CME enabling a rapid response 
to chemoattractant microgradients. Conversely, proliferation is poorly supported due to a 
paucity of robust actin stress fibers, the favoring of CME over RME, and possible 
inhibition of cholesterol biosynthesis and protein prenylation. 
 
Soluble factors play a role in these phenomena by activating integrin-associated 
GFRs, which further enhance mitogenic signaling via c-Src and/or Akt. Despite the relative 
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scarcity of soluble factors in differentiation medium, proliferation is greater on InF due 
possibly to overall greater basal activation of mitogenic signaling induced by ligand-free 
association of integrins and GFRs. Other possible contributory factors include the 
induction of autocrine GF production by heparin [87] or collagen I [88], supported by our 
finding that Akt activity increased after 24 hours in differentiation medium on the stiff 
condition. Proliferation is lower on BaM, however, due to a lack of many of these effects 
and/or potential sequestration of TGFβ1 in the pericellular matrix by collagen IV [89], 
which has been shown to potentiate the GF inhibition of heparin [90]. Finally, despite the 
lack of significance between the fold-change in cell populations, we believe that SMCs on 
InF in growth medium may actually proliferate more than on BaM due to the mechanisms 
described above, but this is obfuscated due to greater spreading and attachment of SMCs 
on InF, resulting in faster saturation of the surface and cell-cell contact inhibition. 
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Figure 4.12: Proposed integrin-mediated signaling mechanisms on InF ECM 
On the InF ECM, we predict that specific signaling motifs driven by integrin-binding – 
with αvβ3 integrin as a prime candidate – induce a proliferative phenotype with low 
migratory capacity. We hypothesize that a proliferative phenotype is favored on InF due to 
strong adhesion, a robust actin cytoskeleton, and a combination of integrin-GFR 
association and RME enabling a concentrated response to GFR activation. Conversely, 
migration is poorly supported due to low focal adhesion turnover. 
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4.6 Conclusion 
We present here a simple in vitro biomaterial system that can parse out the 
complexity of smooth muscle cell phenotype and signaling while under multi-factorial 
exposure to differences in substrate modulus, integrin binding, and soluble factor 
stimulation.  The novelty in our approach was initially syncing cell populations on multiple 
combinations of substrate stiffness and ECM composition, and then probing their 
susceptibility to the synthetic phenotype when dosed with different soluble factor cocktails. 
This simple change from previous methods allowed us to see the true phenotypic diversity 
of SMCs, and helped resolve some contradictions that exist between in vitro and in vivo 
studies.  Coupled with our signaling analysis, we demonstrated that integrin binding is the 
most significant driver of SMC phenotype, and it dictated SMC stiffness sensing and 
sensitivity to soluble factors.  This was modulated primarily by FAK phosphorylation, and 
we propose FAK’s downstream targets are regulated by the integrin heterodimer bound 
and its ability to recruit GFRs and Src into the focal adhesion complex.  In sum, our results 
demonstrate the need to examine any biophysical cue in proper context, and studies of 
mechanosensing in isolation (including our own) may result in incomplete conclusions. 
 
4.7 Future work & considerations 
In the prior discussion we touched upon many areas of potential interest to explore 
in the future. To elaborate on these suggestions, we propose two equally important 
directions: 1) Validate the proposed signaling models with the current in vitro platform 
using advanced cell biology techniques, and 2) Add additional complexity to the in vitro 
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platform to identify other potentially important mechanisms. Next, we will discuss the pros 
and cons of each and potential methods for moving forward in these directions. 
 
4.7.1 Validate the proposed signaling models 
 Since the results in this current work are very interesting and reveal an array of 
SMC behaviors and phenotypes rarely observed in vitro, it is important to validate the 
proposed mechanisms behind the significant differences in proliferation, motility, and cell 
morphology reported here. Perhaps the most crucial component of our hypothetical 
signaling model is the role of CME and RME in promoting migration and proliferation, 
respectively. Their roles may be partially confirmed or denied through the use of inhibitors 
to each type of endocytosis, including siRNAs towards proteins involved in the processes 
[76], small molecule drugs [91], and statins to inhibit RME by depleting cholesterol in the 
plasma membrane [92]. Of course, the choice of inhibitor is important, as non-specific 
effects could confound interpretation of the results, and thus siRNAs against proteins or 
enzymes validated to be directly involved in vesicle formation may be the best choices. 
Other options to further validate the significance of these endocytic pathways include 
immunofluorescent staining and, in the case of RME, detergent extraction and separation 
of cytosolic, membrane, and lipid raft fractions and subsequent immunoblotting for 
proteins of interest i.e. integrins and growth factor receptors. We can then use these tools 
to test our model predictions that inhibiting CME will increase the chemotactic index and 
decrease the speed of SMCs on the BaM composition, and inhibiting RME will decrease 
proliferation on InF. While it would be necessary to carefully avoid confounding effects 
because statins can inhibit SMC proliferation independent of their effects on cholesterol 
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biosynthesis [93], it would be of great interest to the medical field if we were to find that 
statins also inhibit proliferation of SMCs by inhibiting RME.  
We must also elucidate the integrin activity patterns on each ECM composition to 
confirm our suspicions that α2β1 and αVβ3 are major regulators of the behaviors on BaM 
and InF, respectively. This can be investigated with a combination of Western blotting, 
immunofluorescent staining, and integrin inhibition experiments. Immunofluorescent 
staining is likely the most straightforward method, because it permits direct visualization 
of integrins in the plasma membrane, whereas Western blotting will inform us of integrin 
expression, but not activation. Immunofluorescent staining does have the disadvantage of 
not being so easily and rigorously quantified. Integrin blocking or inhibition can also be 
useful, but it is important to know how the method of inhibition acts on the targeted 
integrin. Together, however, these methods would likely be sufficient to confirm or deny 
involvement of our integrins of interest in these phenomena.  
 In addition to differences in integrin expression, we suspect there is a role for Src 
and EGF receptor (and/or other GFRs) transactivation in these phenomena, which is itself 
likely modulated by integrin expression patterns and endocytosis. EGFR transactivation 
via Src is a somewhat common theme in SMC and cancer research, and integrin modulation 
of this type of activity could certainly help explain the differences in proliferation we 
observed. While it would likely be best to investigate this possibility by Western blotting 
phosphorylated and total forms of EGFR and Src during different time points of TGFβ1 or 
stimulation with growth or differentiation medium, it is difficult to get sufficient protein 
yields from samples in the formats used to successfully visualize phosphoproteins via 
Western blot. This could be alleviated with the use of very sensitive secondary antibodies 
139 
 
(i.e. with infrared emitting conjugates), but another approach is, again, immunofluorescent 
staining and co-localization. If either method shows a difference in these activities, the 
application of inhibitors to EGFR (or other GFR) or Src, or transfection with siRNAs, 
should then be used to confirm that these are the signaling proteins responsible for the 
observed behaviors. 
 Another potential mechanism of interest that could help explain our proliferation 
and signaling data is the autocrine production of GFs or cytokines such as VEGFs, PDGFs, 
TNFα, or several interleukins-of-interest. This type of phenomena has been observed in 
SMCs treated with TGFβ1 [94], and it is possible that integrin-ECM interactions could 
modulate this process. With the wide availability of multiplex panels for GFs and 
cytokines, the MAGPIX instrument is an excellent tool to study this type of phenomena, 
and assaying non-phosphorylated proteins in cell culture supernatants is fast and easy. If it 
were discovered that one ECM composition does in fact promote secretion of relevant 
soluble factors, we would next test different integrin inhibitors to see if the secretion is 
reduced, add and remove ECM proteins to replicate or eliminate the effect, or alter the 
ECM concentration to check for ‘dose’-dependency of the effect.  
 Similarly, given that the BaM composition promotes deeper collagen gel invasion 
with growth medium stimulation, we hypothesize that this combination of factors is 
inducing synthesis, secretion and/or activation of one or more matrix metalloproteinases 
(MMPs), the class of enzymes primarily responsible for degrading ECM proteins during 
3D cell migration. Since MMPs are synthesized in an inactive form, it is necessary to test 
for MMP activity, with gelatin zymography for some MMPs, or through the use of 
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cleavage-activated fluorophores and other reporter molecules, with findings confirmed 
with the use of integrin or MMP inhibitors.  
 
4.7.2 Extend in vitro model to recapitulate more complex features of the in vivo 
microenvironment 
Having demonstrated that greater complexity can yield physiologically-relevant 
behaviors in vitro, a natural next step is to further extend the complexity of our in vitro 
model to replicate additional features of the in vivo microenvironment. One simple change 
is the addition of softer and stiffer PEG-PC substrates to cover a wider range of measured 
arterial stiffnesses. We originally chose PEG-PC compositions that ranged from ~10 – 500 
kPa as measured by uniaxial compression testing (see Chapter 2), but the indentation 
mechanical testing method employed here to measure the effective elastic modulus on glass 
cover slips provided dramatically different Young’s moduli of ~40 – 94 kPa. While this is 
unexpected, and it is unclear as to why the new testing or polymerization methods yielded 
such different results, it may explain why stiffness had a much more modest effect than 
anticipated. Nevertheless, since we found that ECM is a major driver of SMC behaviors, 
and substrate stiffness is sensed through integrins and focal adhesions, it could be 
informative to further examine the effects of stiffness on SMC behavior and phenotype by 
repeating the more interesting experiments – especially proliferation in differentiation 
medium and 2D migration – on softer and stiffer PEG-PC substrates (~10 kPa and ~150-
500 kPa, respectively) and characterizing the changes in focal adhesion and cytoskeletal 
properties. These experiments may yield additional information regarding the role of 
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integrins and the cytoskeleton in mediating the phenomena we examined, and may provide 
additional supporting evidence of our endocytosis hypothesis.  
Since there are hundreds of physical and chemical factors implicated in 
atherosclerosis, additional complexity could easily be introduced in the form of a huge 
number of potential soluble factors and relevant ECM proteins. In the microenvironment 
of an intact media there are layers of collagen III in a mesh-like network, layered bundles 
of collagen I fibers, and sheets of elastic laminae (see Chapter 1, Fig. 1.2). However, it is 
unclear if SMCs are actively bound to these other ECM proteins via integrins, or if they 
are merely in proximity. Regardless, including these features in our BaM model may be 
technically infeasible, as we have tried unsuccessfully to covalently attach collagen I and 
III fibers to PEG-PC with sulfo-SANPAH. However, it would likely be trivial to extend 
our 3D invasion model to account for these additional layers of ECM by phenotype syncing 
SMCs on the BaM ECM composition and polymerizing a layer of collagen III directly on 
top, followed by a layer of collagen I. Ideally, polymerization conditions (i.e. pH, 
temperature, monomer concentration, and lysyl oxidase concentration) would be tested and 
optimized to produce a fibrous network that closely matches the properties found in the in 
vivo vascular media including fiber diameter, crosslinking density, and possibly even fiber 
alignment. With this more advanced model we could determine if collagen III and fiber 
morphology impairs or promotes SMC invasion. Even better would be if we could tweak 
the BaM microenvironment to achieve greater confluency and more closely-match the high 
density of SMC packing in the arterial media, possibly by using a higher surface density 
of the BaM ECM proteins. Additionally, it would more physiologically relevant if SMCs 
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on BaM could be induced to produce their own basement membrane proteins on their apical 
surface if they do not already, which would first be tested with immunofluorescent staining.  
While it is a major part of the arterial media, elastin fiber polymerization and 
crosslinking into elastic laminae is a complicated multi-step process [95] and it is unclear 
how, or if, it is possible to synthesize or induce production of native-like elastic laminae in 
vitro. However, it would be interesting to test if any of our experimental conditions induce 
elastin production and crosslinking, which could be confirmed by detecting elastin and 
markers for elastin crosslinking, desmosine and isodesmosine, with an ELISA or 
immunofluorescent staining.  
Additionally, since disordered, fragmented elastin is reportedly found in 
atherosclerotic plaques, we could further investigate the role of elastin by testing the effects 
of different elastin forms – tropoelastin, native soluble elastin, and the cleavage product 
elastin-derived peptide [96] – on the various behaviors and phenotypes observed with our 
in vitro models. We could also easily introduce other common soluble factors such as 
interleukins, tenascin C, TNFα, numerous proteoglycans, and nitric oxide to investigate 
their involvement and modulation of pathological behaviors. Of particular interest are the 
soluble factors secreted by endothelial cells, macrophages, and foam cells, which are 
hypothesized to produce the chemoattractants that induce SMC migration towards a 
plaque. One approach to this is to use endothelial- or macrophage-conditioned media in 
place of, or as a supplement to, the other medias used in our studies. However, it is 
preferable to have a convenient way to evaluate the soluble factors in the conditioned 
medium, and the conditions in which the cells are grown will certainly have an effect on 
the soluble factors they produce, both of which could hamper this approach.  
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Of course, an overabundance of complexity could quickly become detrimental, 
because it may be impossible or infeasible to perform every experimental iteration 
necessary to parse out the relative contributions and effects of each additional feature. 
Luckily, advancements in technology are driving down the costs of experimental lab work 
and making it possible to study very complex biological systems faster, better and more 
easily than ever before, for instance Luminex’s xMAP technology. In conjunction with 
biostatistics, high-throughput ‘-omics’ techniques also enable the examination of hundreds, 
or even thousands, of targets of interest.  
Proteomic techniques, commonly performed with a combination of 2D 
electrophoresis and mass spectroscopy, have identified numerous proteins that are 
differentially regulated in atherosclerotic plaques compared to a healthy media [97], as well 
as in comparisons between plaques histologically-identified as stable or unstable [98]. 
However, most (but not all [99,100]) proteomics studies related to atherosclerosis use 
sectioned tissues from animals or human patients, therefore including proteins produced 
by any resident cell type, including immune cells and endothelial cells, and cannot provide 
any specific information regarding the roles of SMCs. The same is typical of transcriptome 
studies, which have identified many genes associated with atherosclerosis [101,102], but 
the mRNA transcripts could be produced by any of the resident cells.  
While the types of studies described above are very useful for identifying potential 
markers of varying disease states, we are more interested in applying these techniques with 
our complex in vitro model system to get a ‘big picture’ view of how specific element(s) 
of the microenvironment regulate gene transcription and protein expression in SMCs and 
subsequently modulate their behavior. In such an approach it would be appropriate to first 
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consider how various combinations of environmental stimuli modulate the transcriptome, 
in part because it is much easier to measure the mRNA levels of thousands of genes with 
RNA-seq technology than it is to quantify the levels of the same number of proteins with 
mass spectroscopy. While not strictly necessary, in the case of SMCs it would be beneficial 
to perform a whole-transcriptome analysis with sequencing because several microRNAs 
are associated with the contractile and synthetic phenotypes [103–105]. With this data we 
can deduce potential regulatory pathways and identify proteins of interest that may have 
never been considered a priori, then follow up with proteomics techniques to confirm and 
evaluate the expression of any interesting proteins identified from the transcriptome 
analysis. Finally, any interesting findings can be further confirmed with inhibitor studies 
and low-throughput techniques including Western blots and qRT-PCR, as necessary.  
In addition to extending the essential components of our current in vitro model, 
there are other areas of interest that could be examined with some significant changes to 
our model. One of these areas of interest is dynamic mechanical forces, especially 
oscillatory stretch like that which SMCs experience from pulsatile blood flow. However, 
it is unclear how, or if, PEG-PC could be adapted for use in the “Flexcell” devices 
commonly used for such studies, or otherwise how the in vitro model could be modified to 
exert these forces on SMCs. The addition of fluid flow, or oscillatory shear stress, is also 
of interest. While technically it is the endothelial cells of the vascular intima that are 
primarily subjected to fluid flow, this is still of interest with SMCs because they may 
experience these forces following endothelial denudation, as can occur with stent 
implantation or balloon angioplasty. These features can and have been modeled in 
microfluidic devices, but with limited physiological complexity [106]. It would 
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undoubtedly be technically challenging, but it should be feasible to introduce the 
complexity of our in vitro system into a microfluidic model.  
Another extremely interesting feature that would be relatively straightforward to 
integrate with our in vitro model is co-culture with endothelial cells, which has previously 
been shown to profoundly affect SMC phenotype [107–109]. This could be achieved 
indirectly with endothelial cell conditioned media, or by seeding endothelial cells directly 
on top of confluent SMCs. However, since endothelial cells and SMCs in healthy arteries 
are physically separated by connective tissue (mostly collagen), it would be more relevant 
for SMCs and endothelial cells to be separated by a thin layer of polymerized collagen, or 
possibly a synthetic, degradable hydrogel such as PEG-4-maleimide [110]. Ideally, fluid 
flow would also be introduced. The more complex 3D invasion model incorporating both 
collagen I and III described above might be suitable for this purpose, with vascular 
endothelial cells seeded on top of the collagen I gel. This would certainly be technically 
challenging, but if feasible in practice it could ultimately prove to be a useful in vitro model 
of the pathogenesis of atherosclerosis. For instance, with such an in vitro model we could 
introduce oxidized LDL particles and monocytes to a subconfluent layer of endothelial 
cells and see if SMCs are induced to invade and form an artificial plaque. Of course, to be 
truly useful, systems of this complexity must be designed carefully, with reproducibility 
and ease-of-use established as a high priority from the start. 
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